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Abstract 
Prostate gland is the largest accessory sex gland of the male reproductive 
system. As a male accessory sex organ, the normal development and maintenance of 
the prostate gland is regulated by complex factors including steroid hormones, 
extracellular matrix, autocrine and paracrine growth factors. Among these, 
androgens are crucial for the normal development and function of the prostate gland. 
Androgens also play a pivotal role in the etiology and development of prostate 
cancer and benign prostatic hyperplasia. Because the growth of most prostate 
cancers is androgen-dependent, deprivation of androgen by either surgical castration 
or hormone therapy has become the exclusive treatment of advanced prostate 
cancers. Androgens are derived from two sources in mammals: 95% comes from the 
testis and the remaining 5% comes from the adrenal cortex. Synthesis of androgen 
from the testis is strictly controlled by the pituitary gonadotropins (LH and FSH) 
which are in-tum regulated by the gonadotropin-releasing hormone (GnRH) released 
from the hypothalamus. On the other hand, there is considerable evidence showing 
that estrogens also play an important role in the growth of the prostate gland as well 
as in the development of benign prostatic hyperplasia and prostate cancer. However, 
their roles in the male reproductive system and perhaps in prostate cancer still 
remain unclear. 
Hypothalamic gonadotropin-releasing hormone (GnRH) plays an essential 
role in the regulation of reproduction in mammals. After its release from the 
hypothalamic neurons, this decapeptide is transported via the hypophyseal portal 
system and binds to specific receptors on the pituitary gonadotropes. This hormone 
stimulates the gonadotropes to release luteinizing hormone (LH) and follicle_ 
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stimulating hormone (FSH). Androgens are essential for the normal development 
and fimction of the prostate gland. The androgen is mostly secreted by the Leydig 
cells o f the testes. Its synthesis and secretion is in turn regulated by the LH secreted 
by the pituitary gland. The release of LH is in tum-regulated by the GnRH 
synthesized in the hypothalamus. 
Based on the hypothalamus-pituitary-testis hormonal relationship, GnRH 
analogs are developed and used to treat prostate cancers. The major mechanism of 
GnRH agonists to inhibit the growth of tumor is thought to be via the down-
regulation of the pituitary GnRH-receptors which in tum causes a decline in 
gonadotropin secretion. However, recent studies also suggest that GnRH agonists 
may also have a direct anti-tumor effect in the androgen-dependent and -independent 
prostatic cancers by down-regulation of the GnRH receptor expressed locally in the 
tumors. Based on this observation, we attempted to investigate the local gene 
expression of GnRH or its receptor in the normal and neoplastic rat prostate. 
Since GnRH was first isolated from the hypothalamus, it was traditionally 
believed to be produced exclusively by the hypothalamic neurons. However, recent 
evidence has demonstrated that GnRH or its receptor is also expressed in a variety of 
mammalian reproductive organs including testis, ovary, mammary gland and 
placenta, as well as related tumors derived from these organs, suggesting that GnRH 
may exert additional influence in these reproductive tissues or tumors by local 
synthesis of the peptide hormone and expression of its receptor. 
In the present study, we have investigated the mRNA expression of GnRH 
and its receptor in three animal models including the Noble rat model, androgen-
dependent Dunning R-3327-H prostate tumor and an androgen-independent prostatic 
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tumor (AIT) derived from Noble rat which represent the different stages of human 
prostate cancers. The gene expression of this hormone and its receptor was detected 
by molecular biology techniques including RT-PCR and Southem-blot 
hybridization. The results showed that GnRH mRNA but not its receptor, was 
expressed in the normal and dysplastic Noble rat prostate gland (including ventral, 
dorsal and lateral lobes). Both GnRH and GnRH receptor mRNAs were expressed in 
the androgen-dependent Dunning R-3327-H rat prostate tumor. The locally 
expressed and synthesized GnRH and its receptor in this tumor suggests they may 
serve as an autocrine or paracrine inhibitory regulator on the growth of prostate 
cancer cells. However, in the case of AIT tumor, positive expression of GnRH 
mRNA was detected but its expression level was down-regulated as compared to the 
normal prostate and Dunning tumor. This down-regulation was speculated to be 
related to the tumor origin in which the tumor was developed under long-term 
treatment with estrogen and being maintained under androgen ablation. Since GnRH 
receptor was not detected in this tumor line, it was speculated that the locally 
expressed and synthesized GnRH in the AIT tumor might possibly interact with 
other locally expressed growth factors and receptor systems such as EGF, but not 
with its own receptor in order to exert any inhibitory effect on the growth of tumor. 
However, the exact mechanism of the local action of GnRH in the normal and 
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Chapter 1. Introduction 
1.1 Endocrine control of normal and abnormal growth of prostate 
The prostate gland is the largest accessory sex gland of the male reproductive 
system. As a male accessory sex organ, the normal development and maintenance of the 
prostate gland is regulated by complex factors including steroid hormones, extracellular 
matrix, autocrine and paracrine growth factors. Among these, androgens are crucial for 
the normal development of the prostate gland and in maintaining its functional state in 
the adult (Bruchovsky et al., 1975). Although androgens are clearly the most influential 
hormones for the prostate, others such as estrogens, also play some role in the 
maintenance of prostatic function. The effects of these hormones on the prostatic cells 
are mediated via their receptors (Davies and Eaton, 1991; Wilding, 1995). 
1,1,1 Androgen regulation of prostate gland 
In normal human males, the major androgen in circulating blood is testosterone. 
It is produced almost exclusively (95%) by the testis, while the remainder (5%) is 
produced by the adrenal cortex. Under normal physiological conditions, the Leydig 
cells of the testis are the major source of the testicular androgens. The synthesis of 
testosterone by the Leydig cells is regulated by the gonadotropins (luteinizing hormone 
and follicle-stimulating hormone from the pituitary gland), which in tum are regulated 
by the gonadotropin-releasing hormone released from the hypothalamus (Luke and 
Coffey, 1994). A minor source of androgens is from the adrenal cortex. Under the 
influence of adrenocorticotropic hormone, androstene and androstenedion are released 
into the circulation from the adrenal gland. In the blood, 90% of testosterone is bound 
to the hormone binding globulin and only a small percentage of the hormone exists in 
free form. Only the free form of testosterone is able to enter the prostatic cells. In the 
prostate, both testosterone and adrenal androgens are rapidly converted by an enzyme, 
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5a-reductase, to dihydrotestosterone (DHT). 5a-reductase, is a NADPH-dependent 
enzyme, which plays a key role in the prostatic growth and this enzyme is mainly 
located on the nuclear membrane. DHT is three to flve times more potent than 
testosterone itself. Therefore, testosterone is regarded as the prohormone for the 
prostate gland which is in contrast to seminal vesicle. The DHT binds to the androgen 
receptors which are located on the nuclear membrane. The binding of DHT to the 
androgen receptors liberates heat-shock protein (hsp90), and then unmasks the DNA-
binding domain of the receptor, which allows the receptor to dimerize and binds to the 
specific regulatory DNA sequences, so-called ‘hormone response element' of the target 
genes in the genome. This androgen receptor-DNA binding activates the specific 
androgen-regulated genes which in tum stimulate DNA transcription. The messenger 
RNA molecules thus produced encode a number of proteins, including several 
important growth factors, such as epidermal growth factor (EGF), transforming growth 
factor (TGF a and TGF P), insulin-like growth factor I and II (IGF I，II), platelet-
derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) which 
modulate the growth and secretory activity of the prostatic cells (Kirby et al., 1996). 
The androgen and its receptors play an important role in the development and 
morphogenesis of the prostate gland. The androgen regulation of the differentiation and 
branching of the prostatic epithelium is influenced by the prostatic mesenchyme, 
urogenital sinus via epithelial-mesenchymal (or stromal) interactions. These 
complicated interactions have been demonstrated elegantly by Cunha and colleagues by 
tissue recombinant experiments on the epithelial and stromal components of the 
urogenital sinus (Cunha et al., 1983). Their results show that androgens regulate the 
growth, differentiation and morphogenesis of the prostate epithelium indirectly via the 
surrounding stroma. Analysis of the androgen receptors in the tissue components 
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demonstrates that a functional androgen receptor is present in the stroma, not the 
epithelium, during the early embryogenesis is the crucial factor for normal prostate 
development (Wilding, 1995). 
The growth of the human prostate gland occurs in two phases, during puberty 
and after the age of 50, which leads to the condition of benign prostatic hyperplasia. In 
normal adult prostate, unlimited growth of the gland is prevented and the size of the 
gland is relatively constant, being is maintained by a delicate homeostasis between cell 
death and cell proliferation. Androgens are known to be necessary to maintain this 
homeostasis, since either medical or surgical castration results in rapid cell death of the 
epithelial cells by apoptosis and shrinkage of the stroma (Banerjee et al., 1995). The 
DNA content of the prostatic cells is reduced to 10% within 10 days after androgen 
withdrawal. However, some cells remain to survive and they are androgen-independent. 
After replacement of androgen, these remaining androgen-independent cells will 
proliferate and recover their function (Isaacs et al., 1984). 
Androgens also play a pivotal role in the etiology and development of prostate 
cancer. Eunuchs, prepubertal castrates, and men with congenital abnormalities of 
androgen metabolism such as male pseudohermaphroditism do not develop prostate 
malignancy (Hass and Sakr, 1997). The growth of most prostate cancers is androgen-
dependent. In 1940s, Huggins (Huggins, 1940) discovered that androgen deprivation by 
surgical castration could lead to a lowering of the serum level of prostatic acid 
phosphatase and death of most of the prostatic cancer cells. Since then, androgen 
deprivation, by either surgical castration or hormonal therapy, has become the exclusive 
treatment of advanced prostate cancers. The androgen and androgen receptor complex, 
acting as a transcription factor on the genomic DNA, mediates its effects on the target 
cells through transcription control of a specific subset of genes. The influence of the 
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activated androgen receptor on the growth of prostate cancer and its relationship to the 
surrounding stroma are controlled by complex mechanisms that are still not fully 
understood. However, a number of peptide growth factors probably play a crucial part 
in this androgen-related process (Thompson, 1990). TGFp is one of the best studied 
examples, having been shown to play an important role in the processes of prostate 
carcinogenesis, tumor establishment and metastasis (Keski-Oja et al., 1988). TGFp and 
its related family members are shown to influence the transcription of a variety of 
oncogene products such as myc,jun, and fos (Keski-Oja et aL, 1988; Pietenpol et al., 
1990). The tumor suppressor genes such as p53 and RB gene are also shown to be 
involved in this androgen-regulated carcinogenesis of prostate by the transcription 
process as well as the process of apoptosis (Kyprianou and Isaacs, 1988)，but also the 
process of apoptosis controlled by androgen (Kyprianou and Isaacs, 1989). TGPp is 
shown to inhibit the growth of prostate cancer cells in a cytostatic fashion, whereas it 
stimulates the growth of some stromal cells, such as fibroblasts (Wilding, 1991). TGFp 
can alter the response of prostate cancer cells to some positive mitogenic factors, such 
as the members of the epidermal and fibroblast growth factor families (Mckeehan and 
Adams, 1988), suggesting that growth control is in fact a delicate balance between 
positive and negative influences. In addition, TGpp appears to influence metabolic 
pathways important to drug metabolism and steroidogenesis (Chapekar et al., 1990; 
Rainey etal., 1991). 
In summary, the growth of the prostate gland is dependent on androgen. 
However, the relationship between androgen-androgen receptor and the growth of the 
prostate gland is still not fully understood. 
1.1.2 Estrogen regulation of prostate gland 
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There is considerable evidence showing that estrogens also plays an important 
role equal to that of androgens in the growth of the prostate gland as well as the 
development of benign prostatic hyperplasia and prostate cancer (Mawhinney and 
Neubauer, 1979). Of the blood circulating estrogens in young men, 75-90% comes from 
the peripheral aromatization of testosterone to estradiol and of androstenedione to 
estrone, the remaining 10-25% of estradiol being synthesized directly in the testes. 
Early exposure of neonatal mouse to estrogen results in epithelial dysplasia in the 
prostate (Pylkkanen et al., 1991 and 1993). In an animal model of prostate cancer, long-
term treatment (over 52 weeks) of in breed strain Noble rats with testosterone alone 
induces a low incidence (18%) of adenocarcinoma in the rat prostate gland fNoble, 
1977b)，whereas simultaneoues treatment of rats with both testosterone and estrogen 
dramatically increases the incidence of prostate carcinoma and significantly shortens 
the latency period for the cancer development fNoble, 1982). Estrogen has also been 
implicated in the development of benign prostatic hyperplasia by the altered ratio of 
circulating estrogen and androgen. In men with benign prostatic hyperplasia the ratio of 
estrogen to androgen is shown to increase. The functional estrogen receptor has been 
demonstrated in the stromal smooth muscle cells of the human and rat prostates (Brolin 
et aL, 1992; Hiramatsu et al., 1996; Prins et al., 1997). Recently, a novel form of 
estrogen receptor, estrogen receptorP, has been cloned in rat. This novel estrogen 
receptorp is shown to be highly expressed in the reproductive organs including prostate 
(Kuiper et al., 1996). This new estrogen receptorP probably plays an important role in 
prostate function and research on this receptor has aroused much interest. 
During carcinogenesis of the prostate gland, the prostatic androgen receptors 
have been reported to be mutated and the mutated androgen receptors are shown to have 
a higher affinity for estrogen than the normal androgen receptors. Therefore, it is 
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hypothesized that both androgen and estrogen may play some synergism and can 
enhance the process of prostate carcinogenesis (Elo et al., 1995). 
1.2 Gonadotropin-releasing hormone plays a centrol role in 
reproduction 
Hypothalamic gonadotropin-releasing hormone (GnRH), also named as 
luteinizing hormone-releasing hormone (LHRH), plays an essential role in the 
regulation of reproduction in mammals. This hypothalamic decapeptide was first 
demonstrated in 1970 by Schally and colleagues (Schally et al., 1971). After its release 
from the hypothalamic neurons, this decapeptide binds to specific receptors on the 
pituitary gonadotropes via the hypophyseal portal system. This hormone stimulates the 
gonadotropes to release luteinizing hormone (LH) and thus it was named LHRH. This 
term has been supplanted by GnRH, since this peptide not only releases LH from the 
gonadotrophs, but also follicle-stimulating hormone (FSH). It is well know that 
androgens are essential for the normal development and functions of the prostate gland. 
The androgens, particularly testosterone, are mostly secreted by the Leydig cells of the 
testes. Their secretion is in tum regulated by the LH secreted by the pituitary gland. At 
the onset of puberty, the anterior pituitary starts to secrete gonadotropic hormones: FSH 
and LH. FSH acts to initiate spermatogenesis by stimulating the Sertoli cells and is 
essential for the maturation process of spermatids, whereas LH stimulates the Leydig 
cells to secrete the testosterone. 
A negative feedback mechanism works at the hypothalamus-pituitary levels and 
regulates testosterone production by the testis. When testosterone level increases in the 
blood, it inhibits the release of GnRH by the hypothalamus and LH by the anterior 
pituitary. This lower level of LH the decreases testosterone production by the Leydig 
cells. However, when testosterone decreases to a certain level, GnRH is released and 
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stimulates the anterior pituitary gland to release LH which in tum stimulates the 
testosterone production by the testis (Stratakis and Chrousos, 1997). This inhibition of 
LH secretion by testosterone is due to its action on the GnRH secretion. It has been 
shown that testosterone can suppress GnRH expression by the hypothalamus in the 
castrated sheep (Caraty and Locatelli, 1988; Jacson et al., 1991; TilBrook et al., 1991). 
However, the mechanism of the inhibitory action of testosterone on the GnRH 
expression is still unclear. 
1.2.1 GnRHGene 
Mammalian GnRH, or also called luteinizing hormone-releasing hormone 
(LHRH), is a decapeptide ODyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). This 
hormone is synthesized in the cell bodies of hypothalamic neurons and secreted in a 
pulsate manner by their terminals directly into the hypophysio-hypothalamic portal 
circulation. The minuscule amounts of GnRH secreted by hypothalamus as well as its 
modified N- and C-termini made its isolation and structural determination a difficult 
task (Schally et al., 1971). The human and rat GnRH genes have been cloned in the 
1980s. Sequence of GnRH gene were first screened and isolated from a human genomic 
DNA library using synthetic oligodeoxynucleotides directed against the coding 
sequence of the decapeptide (Seeburg and Adelman, 1984). The complete structure of 
the rat and human GnRH genes have been isolated and cloned from the cDNA libraries 
of the human and rat hypothalamus (Adelman et aL, 1986). The mammalian GnRH 
gene consists of four exons and three introns. The first exon consists of 5'-untransIated 
region. The second exon codes for the signal peptide, for GnRH, the enzymatic 
amidation and precursor processing site, and for the N-terminal 11-amino acid residues 
of the GnRH-associated peptide (GAP). The third exon encodes the GAP residues 12-
43，and the fourth exon contains the coding region for the C-terminal 13 amino acids of 
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GAP and also the entire 3'-untranslated part of the mRNA. Analysis of the structure of 
the mammalian GnRH gene has shown that its synthesis is strictly regulated. It is first 
synthesized as a large peptide, the prepro-GnRH precursor. This precursor peptide 
contains a signal sequence (Gly-Lys-Arg) for a mediation, and lastly with a 56 amino 
acid-long fragment, called GnRH-associated peptide (GAP) (Stratakis and Chrousos, 
1997). 
The human GnRH gene is a single gene in the genome and is located on the 
short arm of chromosome 8 (Yang-Feng et al., 1986). It is also a single gene in rat and 
mouse. The location of the three introns relative to exonic sequences are also identical 
in these species. Two alternative transcripts of GnRH have been isolated recently in the 
brain of guinea pig (Linan et al., 1997). 
A mutation of GnRH gene has been described in a mouse strain and this mutant 
strain demonstrates a hypogonadal {hpg) phenotype (Cattanach et al., 1977). Mice 
carrying homozygous genotype for this GnRH mutation showed arrested germ cell 
development and remained sexually immature. Because of the mutated gene, the 
circulating gonadotropin level is undetectable and also shows no demonstratable GnRH 
in hypothalamus. Further analysis of the GnRH gene in the hpg mice reveals a large 
deletion of the third and fourth exons which encode the 45 C-terminal amino acid 
residues of the GAP (Mason et aL, 1986a). This mutant gene does not generate any 
functional GnRH or GAP, as confirmed by immunocytochemistry (Mason et al., 
1986b). The result of this mutation clearly demonstrates the importance of the C-
terminal GAP residue in the synthesis of the GnRH decapeptide. 
The transcription site of the human GnRH gene has demonstrated that the gene 
can be initiated at two different transcription start sites and thus can produce different 
GnRH mRNAs. In the hypothalamus, it has been found that the transcription start site is 
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located at the 61 base pairs upstream of the first exon/intron junction. However, in the 
reproductive tissues, including placenta, testis, ovary and mammary gland derived 
tumor cell lines, a second start site located 579 bases upstream of the hypothalamic site 
is also utilized for transcription (Dong et al., 1993). The significance of this probably 
relates to its regulation by estrogen in different tissues. 
1.2.2 GnRH receptors 
The effect of the GnRH on target cells is mediated by a specific cell membrane 
receptor. The GnRH receptor is primarily located in the limiting plasma membrane of 
gonadotrophs (Clayton et al” 1978; Marian et al., 1983). The GnRH receptor clones 
were first isolated from the cDNA libraries of a mouse pituitary tumor cell line, aT3-l 
cells (Tsutsumi et al., 1992). Analysis of the structure of the human GnRH receptor 
gene showed that the gene contains three exons and two introns (Fan et aL, 1995). 
Subsequently, the structure of the rat GnRH receptor gene has been cloned from the rat 
and mouse (Reinhart et al., 1997). The structure of the GnRH receptor gene is identical 
in human, mouse and rat (Zhouet and Sealfon, 1994; Albarracin et al., 1994; Clay et al., 
1995). The exon sequence of the rat GnRH receptor shows a 77% identity with the 
human exon sequences, whereas the rat promoter sequence has only 57% identity with 
the human promoter sequence. One significant difference between the rat, mouse, and 
human GnRH receptor genes is the location of their start site for transcription (Reinhart 
etal., 1997). 
The GnRH receptor cDNA encodes a protein of 327 amino acids. This 
membrane protein contains seven transmembrane regions which is a characteristic of G-
protein-linked receptors. The GnRH receptor also contains a highly conserved Asp-Arg-
Tyr (DRY) triplet that has been implicated in coupling to G proteins for signal 
transduction. The calculated molecular weight of the receptor protein is 37,684. 
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However, previous studies on solubilized native GnRH receptors show an approximate 
molecular weight of 50,000-60,000 (Iwashita and Catt, 1985; Hazum et al., 1986) 
indicating that the receptor is glycosylated. Three consensus sequences for N-linked 
glycosylation are present in the extracellular domains of the cloned receptor. Further 
analysis of the cloned receptor showed that a potential site for phosphorylation by 
cAMP-dependent protein kinase and protein kinase C is located in the first cytoplasmic 
domain, a potential casein kinase II phosphorylation site is in the second cytoplasmic 
domain, and a potential protein kinase C site is present in the third cytoplasmic domain. 
Another possible phosphorylation site is at tyrosine residue. Several differences exist 
between the GnRH receptor and the members of the G-protein coupled superfamily of 
membrane proteins. The highly conserved Asp-Glu, which is essential for function and 
is found in the second transmembrane region of many receptors is replaced in the 
GnRH receptor by Asp. In addition, the GnRH receptor lacks a polar cytoplasmic C-
terminal region, and has a novel phosphorylation site adjacent to the third 
transmembrane region. The GnRH receptor is also distinct from other G protein 
coupled receptors in that it terminates after the seventh transmembrane domain and 
does not possess a carboxyI-terminal cytoplasmic domain (Stojilkovic et al., 1994). 
The hypothalamic control of the pituitary gonadotropin secretion is strictly 
regulated by GnRH which binds to the cell membrane GnRH receptor in the pituitary 
gonadotrophs. The GnRH and receptor binding leads to a cascade reaction of signal 
transduction, phosphoinositide hydrolysis, calcium signaling, and finally results in 
secretion of LH and FSH. The GnRH receptor in the gonadotrophs is coupled to the 
membrane-bound enzyme phospholipase C (PLC) which can hydrolyze the 
phosphoinositides and thus produce an increase in inositol triphosphate (IP3) and 
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diacylglycerol (DG) concentrations. This leads to release of Ca2+ and activation of 
protein kinase C (Stojilkovic et al., 1994). 
The auto-regulation of GnRH receptor gene expression and protein synthesis by 
GnRH is still controversial: studies from the congenitally GnRH-deficient (hpg) mouse 
have shown that the GnRH can up-regulate its receptor gene expression. Direct 
evidence that GnRH up-regulates its own receptors has been provided. Chronic pulsatile 
treatment with GnRH can induce the synthesis of GnRH receptors in this hpg mutant 
(Young et al., 1983; Young et al., 1985). The up-regulation of GnRH receptor precedes 
the rise in gonadotropin synthesis and release (Detta et al., 1984). These results in the 
hpg mutant suggest an important role for GnRH receptor regulation as one determinant 
of functional activity of gonadotrophs (Clayton, 1989). However, in normal animals, 
the regulation of GnRH receptor by GnRH is in a down-regulation relationship. High 
concentration of this hormone can down-regulation the receptor which involves 
physical internalization of agonist-coupled receptor, whereas low or physiological 
concentration of GnRH stimulates the synthesis of GnRH receptor. This auto-regulation 
of GnRH receptor forms the basis for the effects of constant GnRH infusion or GnRH-
superagonists which leads to the inhibition on LH and FSH secretion. 
Besides the auto-regulation relationship of GnRH receptor by its hormone, the 
receptor is also regulated by steroid hormones synthesized by testis and ovary (Clayton, 
1989). For example, exogenous estrogen treatment of ovariectomized monkeys 
produces a GnRH receptor increase and is coincident with the estradiol-induced LH 
surge (Adams et al., 1981). This data point to a role for estrogen induction of GnRH 
receptors in the process of LH surge. Direct confirmation of the GnRH receptor 
inducing effect of estradiol is obtained from studies in hpg mice where estradiol alone 
doubled GnRH receptor, but when combined with GnRH produced values identical to 
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those of normal littler-mates (Naik et al., 1985). In this respect, estradiol and GnRH act 
synergistically. 
1.3 Therapeutic strategies using GnRH analogs to treat prostate 
cancer 
Based on the hormonal relationship of the hypothalamus-pituitary-gonadal axis, 
analogs of GnRH have been developed and used to treat a number of hormone-
dependent cancers including prostate cancers (Schally et al., 1992; Vacher 1995; Labrie 
et al., 1996), ovarian cancer (Emons et al.,l992) and breast cancer (Santen et al.’ 1986; 
Emones et al., 1994). The major mechanism of action by which GnRH agonists inhibit 
tumor growth is thought to be mediated through the desensitization or down-regulation 
of the pituitary GnRH-receptors which in tum cause a decline in gonadotropin 
secretion. In the treatment of advanced prostate cancers, combined use of GnRH 
agonist and antiandrogen (e.g. flutamide), which is equivalent to surgical castration, can 
achieve a complete androgen blockade and thus can kill most androgen-dependent 
tumor cells. However, recent studies have indicated that GnRH agonists may have a 
direct anti-tumor effect in prostate cancers ( Dondi et al., 1994; Limonta et al., 1992; 
Jungwirth et al., 1997) and also in an androgen-independent rat Dunning tumor (Pinski 
et aL，1994). The latter study also suggests that GnRH analogs may benefit patients 
with androgen-independent prostate cancers or those who have relapsed after androgen 
ablation therapy. However, the mechanism by which GnRH or GnRH/GnRH receptor 
interacts on the inhibition of tumor growth still remains unclear. Recent evidence has 
suggested that the inhibition of tumor growth is probably through the down-regulation 
of GnRH receptor expressed in the tumors (Halmos et aL, 1996; Kaiser et aL, 1993). 
1.4 Expression of GnRH or its receptor in reproductive tissues 
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GnRH plays an integral role in the regulation of reproductive processes through 
its regulation of the secretion of LH and FSH by pituitary gonadotrophs. Since its first 
isolation by Schally and colleagues in 1971 (Schally et al., 1971), this decapeptide is 
believed to be produced exclusively by the hypothalamic neurons. However, the 
expression of GnRH gene or its receptor has also been recently reported in a number of 
reproductive organs. 
1.4.1 Expression of GnRH in reproductive tissues 
Using a sensitive molecular biology technique such as RT-PCR, GnRH mRNA 
transcripts have been detected in the mouse mammary glands of mid-pregnancy, 
lactating, and also during post-lactational stages, whereas GnRH-R mRNA transcripts 
are not detected in the mammary glands of similar functional stages (Ikeda et al., 1995). 
1.4.2 Expression of GnRH and its receptor in pituitary and reproductive 
tissues 
Besides GnRH receptor, GnRH mRNA is also found to be expressed in the rat 
anterior pituitary gland by using the RT-PCR amplification (Pagesy et al., 1992). 
Moreover, GnRH expression is also detected in normal and neoplastic human pituitaries 
by RT-PCR and in-situ hybridization (Sanno et al., 1997). The expression of GnRH and 
its receptor in organs, other than the hypothalamus and pituitary gland has altered the 
classical view on the endocrinology of this hormone. This implies that GnRH might 
function as an autocrine-paracrine control of the gonadotrophs in the pituitary gland and 
also cells in other reproductive organs. 
Expression of both GnRH and its receptor has been detected in some tumor cell 
lines of reproductive organ origins. For example, expression of GnRH and its binding 
sites are detected in an androgen-dependent prostatic tumor cell line, LNCaP and in an 
androgen-independent prostatic tumor cell line, DU 145 cells by RT-PCR technique 
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(Limonata et al., 1996). The possible role performed by the local expression and 
synthesis of GnRH on the tumor cell proliferation is demonstrated by the treatment with 
GnRH antagonist. When the LNCaP cells cultured in steroid-free condition, and DU 
145 cells cultured without serum, are treated with an GnRH antagonist, both cell lines, 
are stimulated to proliferate. Under the similar culture conditions, epidermal growth 
factor (EGF) is also shown to stimulate the proliferation of both LNCaP and DU145 
cells. However, when the cells are treated with both EGF and an GnRH agonist, the 
GnRH agonist appears to counteract the proliferating effect in both cell lines. These 
studies have provided a view on the mechanism of action of GnRH in prostatic cancer 
cells by functioning as a growth inhibitory factor through reducing the EGF binding 
sites in the autocrine-paracrine control of androgen-dependent and androgen-
independent proliferation of prostatic tumor cells (Limonta et al., 1996). 
Besides the human prostatic cancer cell lines, GnRH receptor is also expressed 
in an androgen-independent Dunning rat prostatic cancer R-3327-AT-l (Pinski et al., 
1994) and an androgen-dependent Dunning prostatic cancer R-3327-H (Jungwirth et al., 
1997). In addition, experiments using GnRH analogs have shown that the analogs can 
inhibit the growth of these two prostatic tumors and also down-regulate the expression 
of the GnRH receptor in the Dunning prostatic carcinoma R-3327-H ( Pinski et al.， 
1994; Jungwirth et aL, 1997). 
Gene expression of GnRH and its receptor are also found in adult human and 
mature rat testis. In rat, expression of GnRH mRNA is detected in both Sertoli cells and 
spermatogenic cells of some seminiferous tubules. However, in human, the expression 
of GnRH mRNA is detected only in spermatogenic cells in some seminiferous tubules. 
In addition the GnRH receptor is localized to the Leydig cells. This leads to a view that 
the GnRH produced by the Sertoli cells in the seminiferous tubules could react with the 
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GnRH receptors present in the interstitial cells in a paracrine regulatory mode (Bahk et 
al., 1995). 
Besides the male reproductive tissues, GnRH and its receptor have been 
detected in female reproductive tissues. For example, GnRH and its receptor are 
expressed in human breast tissues with fibrocystic disease and invasive ductal 
carcinomas. However, quantitative determinations of mRNA by dot blot analysis do not 
reveal significant differences between the malignant and nonmalignant breast samples 
on either GnRH or GnRH receptor gene expression (Kottler et al, 1997). GnRH gene 
expression and GnRH-binding sites are also identified in human breast carcinoma cell 
lines ZR-75-1, MCF-7 and MDA-MB-231. Treatment with GnRH analogues also shows 
that the analogues can inhibit the proliferation of tumor cells, suggesting that GnRH 
may serve as an autocrine regulatory role in the mammary gland (Harris et al., 1991). 
Moreover, GnRH or its receptor is also found expressed in other female reproductive 
tissues including ovary, ovarian tumor and placenta (Oikawa et al., 1990; Chieffi et al., 
1991; Karkar et al., 1992;1994). 
1.5 Animal models for the study of prostate cancer 
The prostatic carcinogenesis is a multi-step process which involves initiation, 
malignant transformation, growth and progression to become androgen-dependent 
tumors which may become androgen independent in advanced stage and metastasis. 
Three animal models including Noble rat inducible model, androgen-dependent rat 
Dunning prostatic tumor and androgen-independent Noble rat prostatic tumor, which 
represent different stages of prostate cancer, were used in the present study. 
1.5.1 Noble rat inducible model 
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The use of Noble rat for the study of prostate cancer began in 1960s. In this 
model, sex steroids are used to induce prostate cancer. It is based on the etiology of the 
disease, particularly the role of sex hormone. In the original protocol, subcutaneous 
implantation of estrone pellets (10 mg/pellet) was used fNoble, 1977a and b). In a later 
modified protocol, both testosterone and estrone pellets were implanted. This 
modification can shorten the latency period for the induction of prostate cancer and thus 
increase the incidence rate of this cancer in this rat strain (^oble，1977a and b). This 
protocol of combined hormonal treatment with both testosterone and estrogen was then 
further improved by implantation of steroid-filled Silastic tubings instead of steroid 
pellets (Drago, 1984). The duration of induction is then shortened to a period of 18 
weeks to 9 months depending on the stages of cancer induced. This rat model can 
induce with a 100% rate of a premalignant lesion, termed dysplasia, in the Noble 
prostate gland. This premalignant lesion, dysplasia, is believed to be identical to the 
prostatic intraepithelial neoplasm (PIN) in human prostate, and will further develop into 
carcinoma. 
L5.2 Androgen dependent rat Dunning prostatic tumor 
The original Dunning tumor was first observed by Dr. Dunning by autopsy in a 
22 month-old retired male rat breeder of the Copenhagen strain in 1961 (Dunning, 
1963). This tumor is believed to have originated in the dorsal prostate and is classified 
as a papillary adenocarcinoma with no metastases found. This tumor is also described 
and classified by its pathology as well-differentiated adenocarcinoma composed of 
distinct well-formed acini with acidic (eosinophilic) secretions inside, which is similar 
to the normal dorsal lobe of the rat prostate. 
Dr. Dunning denoted this tumor as the R-3327 and serially passaged it into both 
syngeneic Copenhagen male rats and F1 male hybrids of the Copenhagen male and 
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Fischer female cross. Following serial in vivo passages of the R-3327 tumor in the 
original Dunning's laboratory, several variant sublines were subsequently developed 
from the original R-3327 line. For example, a R-3327A subline is an androgen-
independent fast-growing squamous cell carcinoma lacking androgen receptors and 5a-
reductase activity (Isaacs et al., 1982). 
Since 1974，the R-3327 tumor has been maintained and extensively 
characterized by Isaacs and colleagues at Johns Hopkins Hospital (Smolev et al., 1977a 
and b) and given the designation as the H subline. This H subline is a heterologous 
tumor composed of both androgen-dependent and androgen-independent tumor cells 
(Smolev et al., 1977a; Isaacs et al., 1981). The original phenotype and characteristics of 
the H subline have been maintained by continuous serial passage in intact male hosts. 
In the course of routine passage of the H-subline tumor in intact male hosts, 
random tumor progression has occurred probably due to the genetic instability of the 
tumor in an occasional rat within a single passage, and developed into an androgen-
insensitive, rapidly growing, anaplastic tumor termed the AT-1 which rarely produces 
distant metastases (Isaacs et al., 1982). After continuous serial passage, this AT-1 
subline further progressed to give rise to two metastatic anaplastic tumors: MAT-LyLu 
(Isaacs et al., 1981) and MAT-Lu cancer (Lazan, et al., 1982). Additional progression 
randomly occurring upon serial passages of the H tumor has given rise to two distinct 
androgen-insensitive, rapidly growing, non-metastatic, anaplastic tumors termed the 
AT-2 and AT-4 variants, respectively. 
The wide diversity of Dunning tumor subtypes has allowed this tumor model to 
be used to study the mechanism of prostate cancer progression and metastasis, and their 
responsiveness to varieties of therapies including hormonal, radiational, chemo- and 
immuno-therapy. 
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i .5 . i Androgen-independent prostatic carcinoma line of Noble rat 
The androgen-independent prostatic carcinoma line of Noble rat is also a 
transplantable tumor. It was originally derived from an androgen-stimulated subline 
Nb-2Pr-A developed by Noble O^oble, 1980b). This subline was originated from the 
Nb-2Pr-E line that arose from the dorsal-lateral prostate of an estrone-treated Nb rat 
which has been under treatment for 57 weeks pSfoble and Hoover, 1975; NobIe, 1977b 
and 1980a). Following transplantation of Nb-2Pr-E into the testosterone-treated 
syngeneic male Noble rats, the tumor evolved into the androgen-stimulated Nb-2Pr-A 
subline. This tumor subline grows rapidly in androgenized or intact male rats but slowly 
in castrated males. The tumor fragment was transplanted into the dorsum ofmale Noble 
rats which had been castrated for 2 weeks. The tumors are then harvested when they 
achieve a volume of2.0 cm3 (Ho, et al., 1988). 
1.6 Aim ofstudy 
In the present study, three animal models including Noble rat model, an 
androgen-independent prostatic tumor (AIT) derived from Noble rat and androgen-
dependent rat Dunning prostatic tumor were used to study different stages of prostatic 
cancer. Recent evidence has demonstrated that GnRH or its receptor is also expressed in 
a variety of mammalian reproductive organs including testis, ovary, mammary gland 
and placenta as well as related tumors derived from these organs. A hypothesis is 
proposed that extra-hypothalamic expression of GnRH may exert a local regulatory 
function in these reproductive organs as well as tumors derived from these organs, in 
addition to its endocrine function in pituitary. However, the functional significance of 
the local expression of this hormone and receptor still remains unclear. Since GnRH is 
rapidly degraded at the pituitary level, its circulatory levels are extremely low. Recent 
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studies have shown that GnRH receptor is expressed in rat Dunning prostate tumors, 
human prostate cancers and derived cancer cell lines. This strongly suggests that GnRH 
may be synthesized at the level of the prostate gland and the direct effects ofGnRH and 
its analogs in the prostate may be mediated through its receptor. In addition, GnRH 
analogs are shown to inhibit the growth of androgen-independent and androgen-
dependent prostate tumors, suggesting that these analogs may have a direct effect on the 
prostate, in addition to their effects on the pituitary gonadotropes. The aim of the 
present study is to investigate the GnRH or its receptor expression in the different 
stages of prostate cancer using three animal models including Noble rat model, an 
androgen-independent prostatic tumor (AIT) derived from Noble rat and androgen-
dependent rat Dunning prostatic tumor. The gene expression of this hormone and its 
receptor was detected by molecular biology techniques including RT-PCR 
amplification, DNA sequencing and Southern blot hybridization. 
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Chapter 2. Material and methods 
2.1 Origin and supply ofNobIe rat 
Noble rat is an inbred strain which was originally developed by Dr. RX. Noble 
of the Cancer Research Centre in Vancouver (^oble, 1977a). He selected and 
developed this black-hooded rat colony from the original stock derived from Dr. J. B. 
Cullop's laboratory at McGill University in 1940s. In 1970s, the Medical Research 
Council of Canada designated this strain as Noble (Nb) rat after evaluation on its 
genetics and degree of inbreeding contributed by Dr. Noble .The ancestor of Noble rat 
was still ambiguous and was believed that it was the out-cross between the Long-Evans 
rats and Wistar rats. The offspring were then randomly bred and only the black-hooded 
rats were selected for later experiment and used as breeders. 
Breeders of Noble rats were originally obtained from the Charles River 
Breeding Laboratories, Japan in 1996. They were then bred by the Laboratory Animal 
House, The Chinese University of Hong Kong. In the present study, Noble rats of 12-
13-week old were used for the RNA extraction as well as steroid implantation. 
2.2 Induction of prostatic dysplasia in Noble rat prostate gland by 
long-term treatment with steroids 
2.2.1 Chemicals 
Most of the chemicals used in this study were obtained from Sigma Chemical 
Company (St. Louis, USA) and Fluka (Buchs, Switzerland). 
2.2.2 Preparation of steroid hormone-filled Silastic tubings 
Slastic® laboratory tubings (with inner diameter of 1.67 mm and outer 
diameter of3.18 mm; Dow Cowing, 508-008, Michigan, USA) cut with suitable lengths 
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were used to fill with sex steroids. Tubings of 2cm long were filled with testosterone (T, 
Fluka), whereas the 1-cm tubings were filled with 17 P-estradiol (E2) or 
diethylstilbestrol (DES; Sigma chemical Company, USA). The two ends of the drug-
filled tubings were then sealed with Silastic medical adhesive (silicone type A; Dow 
Coming). When the adhesive became hardened, the tubings were soaked ovemight in 
70% alcohol in order to remove the residual powders of hormone or drug adhered on 
the surface of the tubings and to ensure the tubing were completely sealed. The tubings 
were further immersed in 0.05 M phosphate buffered saline (PBS) for another 2 days. 
After blotting dry with Kimwipes, the tubings were stored at 4°C for later use. 
2.2.3 Surgical implantation of Silastic® tubings 
Mature male Noble rats (12-13 weeks old) were anaesthetized by intraperitoneal 
injection of 7% chloral hydrate (0.5 ml/lOOg body weight). The implantation site was 
made over the skin between the scapulae. After hair-shaving with an electric clipper 
and cleaning with 70% alcohol, the skin was cut and a subcutaneous pocket was made 
by blunt dissecting beneath the skin in a caudal direction with blunt forceps in order to 
accommodate the tubings. Testosterone-implants (T) were inserted and placed over the 
left scapula while the estrogen-implants (DES or E2) were placed on the right side. 
After implantation, the skin was sutured and sprayed with a permeable wound dressing 
(Smith & Nephew Medical limited, England). The animals were then housed in cages 
and fed on normal chows and drinking water. Post- surgery observation was made twice 
a week. 
2.2.4 Protocols of hormonal treatments 
A total of thirty Noble rats were used in the experiment of hormonal treatment. 
The animals were divided into three group: 1) combined T+E2, 2) combined T+DES 
and 3) control. For rats under hormonal treatment, two 2-cm tubings filled with 
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testosterone and one 1-cm tubing filled with either E2 or DES were implanted 
subcutaneously. For the controls, the aged-matched Noble rats, without implantation of 
tubings were used. The animals were sacrificed after 4 and 9 months treatments with 
hormones. For 9 months treatments, the tubings were replaced with new ones in every 3 
months. 
2.3 Androgen-dependent rat Dunning prostatic adenocarcinoma 
Dunning rat prostatic adenocarcinoma is an animal model of prostatic cancer 
originally developed by Dr. Dunning (Dunning, 1963). It is a transplantable prostatic 
tumor which was developed spontaneously from the dorsal prostate in an aged 
Copenhagen rat. This tumor was classified by its pathology as a well-differentiated 
prostatic adenocarcinoma. A number of sublines were then developed (Isaacs et al., 
1979). The R-3327-H subline used in the present study is an androgen-dependent tumor 
which was developed from the R-3227 line. This tumor is maintained subcutaneously in 
nude mice and its growth is stimulated by exogenous androgen. For tumor 
transplantation, one 0.2-cm3 solid tumor and one 1-cm Silastic® tubing (with inner 
diameter 1.96 mm and outer diameter 3.18 mm, Dow Cowing, Michigan, USA) filled 
with testosterone were implanted into the dorsum region of the nude mice,. The tumor 
was then maintained and grown in the nude mice for four months before harvest. The 
R3327-H Dunning prostatic tumor used in our experiment was a generous gift provided 
by Professor Y. C. Wong of the Department of Anatomy, The University of Hong 
Kong. 
2.4 Androgen-independent prostatic carcinoma line (AIT) of Noble 
Rat 
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The androgen-independent prostatic carcinoma line of Noble rat was originally 
derived from an androgen-stimulated subline Nb-2Pr-A by Noble (Noble, 1980b). This 
subline originated from the Nb-2Pr-E line that arose from the dorsal-lateral prostate of 
an estrone-treated Nb rat which has been under treatment for 16 weeks pvJobIe and 
Hoover, 1975; Noble, 1977b and 1980a). Following transplantation of Nb-2Pr-E into 
the testosterone treated syngeneic male Noble rats, the tumor evolved into the 
androgen-stimulated Nb-2Pr-A subline. This tumor subline grows rapidly in 
androgenized or intact male rat but slowly in castrated males. The tumor fragment was 
transplanted into the dorsum of male Noble rats which had been castrated for 2 weeks. 
The tumors were then harvested when they achieved a volume of 2.0 cm3 (Ho, et aL, 
1988). The cDNA of the androgen-independent prostatic carcinoma line (AIT) ofNoble 
rat used in our experiment was kindly provided by Dr. Shuk-Mei Ho ofthe Department 
ofBiology, Tufts University , USA. 
2.5 Detection of mRNA expression of gonadotropin-releasing 
hormone (GnRH) in normal and neoplastic rat prostates 
2.5.1 Preparation of tissue for total RNA extraction 
Five normal Nb rats as well as five Nb rats which have been treated with T+E2 
or T+DES for 4 months or 9 months were used for the RNA extraction. The rats were 
anaesthetized by exposure to ether in a closed chamber. Blood was quickly withdrawn 
from the dorsal aorta of the anaesthetized rats in order to minimize the effects of the 
contamination of blood-bom ribonucleases on the extracted RNA. The urogenital tract 
was exposed by a lower abdominal incision and removed en bloc (including seminal 
vesicles, prostate glands, vas deferens and urethra). The ventral prostate, dorsal 
prostate, lateral prostate, coagulating gland and seminal vesicles were quickly dissected 
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over an ice-bath. For positive control, the pituitary gland and hypothalamus were also 
dissected from the brain. The nude mice which had been bearing the Dunning tumor for 
four months were sacrificed by cervical dislocation. The tumor was then quickly 
dissected from the dorsum region. The dissected prostate gland, seminal vesicle, 
pituitary gland, hypothalamus and the Dunning tumor were deep frozen in liquid 
nitrogen and stored at -70°C for subsequent RNA extraction. 
2.5.2 TotalRNA Extraction 
The total RNA from the frozen tissues was extracted by using a Trizol reagent 
(GibcoBRL, USA). The reagent contains phenol and guanidine isothiocyanate mixture, 
and is used in a single-step method for RNA isolation developed originally by 
Chomizynski and Sacchi (1987). First, the tissue was homogenized with a pestle in a 
small mortar under liquid nitrogen. About 50-100 mg homogenized tissue was 
incubated in 1-ml Trizol reagent in a microcentrifuge tube at room temperature for 5 
min. Chloroform (200 ^1) was then added to the homogenate and the mixture was 
shaken vigorously for 15 seconds. After 3 min incubation at room temperature, the 
aqueous phase and organic phase was then separated by centrifugation at 12,000 xg for 
15 min at 4°C. The supernatant, i.e. the aqueous phase, was transferred to another 
microcentrifuge tube and an equal volume of isopropyl alcohol was added. After 
mixing, the mixture was incubated again at room temperature for 10 min to let the RNA 
precipitate. The RNA pellet was obtained by centrifugation at 12,000 xg for 10 min at 
4°C. The supernatant was removed carefully and the pellet was washed with ice-cold 
70% ethanol. The pellet was then air dried and redissolved in 15 ^1 of diethyl-
pyrocarbonate (DEPC) treated water. The resuspended RNA was quantified by 
measuring its absorbance at 260 nm in an UV-visible spectrophotometer (Gene Quat II 
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RNAyDNA Calculator, Pharmacia Biotech, USA). The sample was stored at -70°C until 
required. 
2.5.3 Reverse transcription polymerase chain reaction (RT-PCR) 
The reverse transcription of total RNA to complementary DNA was performed 
by using a commercial kit ( S U P E R S C R I P X T M Preamplification System for First 
Strand cDNA Synthesis, GibcoBRL，USA). About 6 ^g of total RNA and 2 ^1 Oligo 
(deoxythymidine) (0.5 |ig/^d) was dissolved in DEPC-water to a final volume of 24 ^1. 
The mixture was incubated at 70°C for 10 min. Other components (including 4 ^1 of 
10x PCR buffer, 4 i^l of 25 mM MgCl2, 2 i^l of 10 mM dNTP mix and 4 i^l of 0.1 M 
DTT) were added to the mixture and incubated at 4°C for 5 min. After incubation, the 
reverse transcriptase (400U) was added to the mixture to synthesize the cDNA at 42°C 
for 50 min. The reverse-transcription was then stopped at 70°C for 20 min. After the 
reaction was completed, 2 |il of RNase H was added to the cDNA components and 
incubated at 37°C for 15 min in order to digest the remaining total RNA. The cDNA 
was stored at - 20°C until required. 
The cDNA samples of the prostates (including ventral, lateral and dorsal lobes), 
seminal vesicles, coagulating gland, pituitary gland and hypothalamus obtained from 
normal Noble rats and rats which had been treated with T+E2 or T+DES for 4 months 
or 9 months, Dunning tumor and AIT were processed for polymerase chain reaction to 
amplify the gonadotropin-releasing hormone (GnRH) mRNA. Two pairs of primers 
specific for rat GnRH were designed according to the published sequence for the rat 
GnRH gene (GENEBANK, accession number M31670; Bond et a!” 1989). These pairs 
of primers would amplify a 260-bp and a 230-bp DNA fragment of the rat GnRH gene 
respectively. The two different pairs of the primers used in this experiment had the 
following sequence. 
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Sense primer: 
SF2： 5'-GAA ACG ATC CCC AAA CTG ATG-3' 
Antisense primers: 
SRi: 3'-TGC CCA GCT TCC TCT TCA ATC-5' 
SR2： 3'-GCT CCT CGC AGA TCC CTA AAG-5' 
A reaction mixture for the first PCR amplification was prepared as follows. It 
consisted of 1 fil of reverse-transcription reaction product or cDNA, 1 ^1 each of the 
sense SF2 and antisense SR\ primers (20 ng/^il) which would amplify a 260-bp DNA 
fragment of the rat GnRH gene, 2.5 ^1 of 10X PCR buffer, 1.5 i^l of25 mM MgCl2, 0.5 
…of 10 mM dNTP mix, 0.2 ^1 of Taq DNA polymerase (GibcoBRL) and 17 ^1 of 
autoclaved milliQ water. 100 i^l of mineral oil was added on the top of the reaction 
mixture in order to prevent evaporation during the PCR process. The mixture was then 
incubated in a thermal cycler (Robo-Cycler, Stratagene, USA). The conditions of the 
PCR were as follows: the mixture was first heated to 94°C for 4 min, followed by 30 
cycles which consisted of 1 minute at 94�C for denaturing of cDNA, 1 minute at 55°C 
for annealing of primers, and 1 minute at 72°C for extension of newly-synthesized 
DNA strand. The reaction was stopped at 72°C for 10 min. The PCR products (10 ^1) 
were then analyzed by electrophoresis in a 1% agarose gel in lx TAE buffer with 0.2 
mg/ml ethidium bromide. The results were analyzed under UV illumination (312 nm) 
and photographs were taken for records. 
After the first PCR, the DNA products from the ventral prostate of the normal 
Noble rat, the rat Dunning tumor and AIT were used for a second PCR amplification. 
The second PCR was performed in order to further amplify the GnRH mRNA signal. 
This was done by using 1^1 of the first PCR DNA product which was used as the 
template, 1 |il of each of sense SF2 and antisense SR2 primer which would amplify a 
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230-bp DNA fragment of the GnRH gene. The reaction conditions were the same as the 
first PCR and 30 PCR cycles were applied. After the PCR reaction, all the PCR 
products were separated by electrophoresis in 1% agarose gel and the DNA fragments 
were extracted and purified from the agarose gel for subcloning. 
2.5.4 Purification of DNA fragment from agarose gel 
The DNA products amplified by the second PCR reaction of the cDNA samples 
from the normal Nb rat ventral prostate, rat Dunning tumor and AIT for the GnRH gene 
amplification were extracted and purified from the agarose gel after electrophoresis. 
The DNA purification was performed by using a SephagIas BandPrep Kit (Pharmacia 
Biotech). The slices of agarose containing the DNA bands were cut from the gel and 
transferred to a 1.5 ml microcentrifugetube. 250 fil of Gel Solubilizer was added to the 
tube and incubated at 60°C for 10 min until the agarose slice was dissolved. After the 
dissolution of the gel, 5 |il of the Sephaglas BP suspension was added to the dissolved 
gel slice and further incubated for 5 min at room temperature. The mixture was agitated 
gently at minute intervals. The Sephaglas pellet was spun down at slow speed for 30 
seconds in a microcentrifuge. The supematant was removed. The pellet was kept and 
washed with 80 |il of Wash Buffer for 3 times. The pellet was then air dried for 10 min 
and dissolved in 10 i^l of elution buffer. The eluted DNA was obtained by 
centrifugation at 14,000 xg for 1 min and the supematant was transferred to a clean 
microcentrifuge tube. The eluted DNA samples were stored at -20°C until required. 
2.5.5 Subcloning ofDNA into vector 
The extracted DNA fragments were first processed for 5'-phosphoryIation and 
blunt-ended for ligation with the vector. The reaction mixture was prepared as follow: 
10 ^1 of extracted DNA, 2 ^1 of 0.1 mM ATP, 1 ^1 of 10 mM dNTP mix, 1 ^1 of 
Klenow fragment (GibcoBRL), 1 fil of T4 Kinase (GibcoBRL) and 4 ^1 of 10x T4 
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kinase buffer were mixed. The mixture was dissolved in 30 ^1 of water and incubated at 
37°C for 60 min. After the reaction, the DNA sample was purified by a phenol and 
chloroform mixture (ratio 1:1). The extracted DNA in the aqueous phase was removed 
and precipitated with 2 volume of absolute alcohol for 15 min at -70°C. The DNA was 
obtained by centrifugation at 12,000 xg for 10 min at 4°C and the pellet was redissolved 
in 10 |il of water. 
The cDNA fragments of the GnRH or its receptor were subcloned into the 
pBluescript SK (pSK) vector. The vector was first linearized and the linearization 
mixture was performed as follows: 5 |il of pSK (4 ^g/^l), 2 ^1 of Sma I (lOU/^il) 
(GibcoBRL), 3 ^1 of 10x reaction buffer and 20|il of water. The mixture was incubated 
at 30°C for 60 min. When the reaction was complete, the linearized vector was 
processed for dephosphorylation and performed as follows: 2 fil of calf intestinal 
alkaline phosphatase (CIP), 5 ^1 oflOx CIP buffer and 10 |nl ofwater were added to the 
linearized vector mixture. The mixture was incubated at 37°C for 30 min. The 
dephosphorylated linearized vectors were purified by the phenol and chloroform 
mixture (ratio 1:1). The extracted vectors were precipitated by ice-cooled absolute 
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alcohol. The linearized vectors were obtained by centrifugation at 12,000 xg for 10 min 
at 4°C and redissolved in 10 |xl water. 
The ligation reaction was performed and the reaction mixture was prepared as 
follows: 5 |il of extracted DNA (0.5 ^ig), 1 ^1 of linearized vector, 1 ^1 of DNA ligase 
(lOU, GibcoBRL) and 2 |il of 5x ligation buffer. The mixture was diluted with water to 
a final volume of 10 ^1 and incubated ovemight in a thermal cycle (GeneAmp PCR 
system 9600，Perkin Elmer, USA) at 16°C. 
After ligation, the plasmids with the inserted DNA were transferred to XL-1 
blue E.coli competent cells by electroporation. 5 |il of ligation mixture containing the 
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plasmids and 40 |il of E. coli competent cells were put in a 0.2 cm cuvette specific for 
electroporation (BioRad, USA). The cuvette was placed in a small chamber with 
electrodes connected to power supply (Gene pulse II System, BioRad, USA), and 2.5V 
was discharged across the electrodes. After electrical discharge, 1 ml of2XYT medium 
was added to the competent cells. The transformation mixture was transferred to a new 
microcentrifuge tube and incubated at 37°C for 45 min. 
The transformed E.coli competent cells were allowed to grow in a LB agar plate 
for selection. The LB agar contained 100 |il of ampicillin (50 ng/mI), 40 |il of5-bromo-
4-chloro-3-indolyl-P-D-galactoside (x-gal; 200 mg/ml) and 50 ^1 of isopropylthio-6-D-
galactoside (IPTG; 10 mg/ml). The suspended competent cells (200 ^1) were plated 
onto the LB plate and spread well on the surface of the agar plate. The agar plate was 
incubated in an inverted position at 2>TC for 12-16 hours. The plate was then stored at 
4°C for another 4 hours for the color development by the p-galactaside activity. After 
the color development, a white single bacterial colony representing the recombinant 
was transferred with a toothstick to a loosely capped 15-ml tube which contained 2 ml 
of LB medium with ampicillin (50 ng/ml). The culture medium was then incubated at 
37°C ovemight with vigorous shaking. 
The recombinant plasmid DNAs were extracted in small scale from the culture 
ofthe transformed E.coli competent cells. 1.5 ml of the culture medium containing the 
recombinant colony was poured into a microcentrifuge tube. The bacteria were pelleted 
by centrifugation at 12,000 xg for 1 min at room temperature and the medium was 
removed by aspiration. The bacterial pellet was resuspended in 150 |il of buffer pl (25 
mM Tris, pH 8.0; 50 mM glucose). After resuspension of cells, 150 ^1 ofbuffer p2 (0.2 
N NaOH, 1% SDS) was added and the bacterial content was mixed by invertjng the 
tube rapidly five times in order to Iyze the cells. After lysis of cells, 150 ^1 of ice-cold 
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buffer p3 (3.0 M potassium acetate, pH 4.8) was added to the bacterial content and kept 
on ice for 15 min. The mixture was centrifuged at 14,000 xg for 15 min at 4°C. The 
supernatant was transferred to a new tube and 0.7 volume of isopropanol was added. 
After mixing, the DNA was precipitated at room temperature for 10 min. The 
precipitated DNA was pelleted by centrifugation at 12,000 xg for 15 min at 4°C and the 
DNA pellet was then washed with 1 ml 70 % ethanol and dried under vacuum. The 
plasmid DNA was dissolved in 30 i^l water and quantified with a spectrophotometer by 
measuring the absorbance at 260 nm. 
The plasmid DNA prepared from the transformed E.coli cells was analyzed by 
digestion with restriction enzymes BarrM I and EcoR I. The reaction mixture was 
prepared as follows: 2\i\ of the DNA solution (2^g), 1 ^1 of 10x restriction enzyme 
buffer and 2 units of each BamH I and EcoR I were mixed in 8 |il water. The reaction 
mixture was incubated at 37�C for 1 hour. The digested DNA fragments were analyzed 
by electrophoresis in a 1% agarose gel. 
2.5.6 Nucleotide sequencing 
The plasmid DNAs which contained the inserted cDNA fragment with right size 
were processed for nucleotide sequencing by using a dideoxy/Sanger method 
commercial kit ( T 7 s e q u e n c i n g T M Kit ;Pharmacia Biotech, USA; Sanger et aL, 1977). 
The procedure used was as follows: 32 ^1 ofplasmid DNA (1.5-2.0 |ig) and 8 juI of2M 
NaOH were mixed in a microcentrifuge tube followed by an incubation for 10 min at 
room temperature for denaturing the double-stranded DNA template. 7 ^1 of 3M 
sodium acetate ( pH 4.8)，4 i^l of distilled water, 120 ^1 of absolute ethanol were then 
added to the denatured DNA and placed at -70°C for 60 min for DNA precipitation. The 
precipitated DNA was pelleted by centrifugation at 12,000 xg at 4°C for 15 min. The 
supernatant was removed and the DNA pellet was washed with ice-cold 70% ethanol 
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and dried under vacuum, and finally redissolved in 8 ^1 of water. 2 |il of T7 or T3 
primer (10 pmol/^il), 2 i^l of annealing buffer and 2 ^1 of DMSO were added to the 
DNA followed by an incubation at 65�C for 5 min. The mixture was then kept at 37�C 
for 10 min and at room temperature for at least 5 min. 3 |il ofLabelling Mix-dCTP, 1 |il 
of a-35s-dCTP and 2 i^l of diluted T7 DNA polymerase (cold enzyme dilution buffer : 
T7 DNA polymerase = 4:1) were added to the DNA. The mixture was mixed well and 
incubated at room temperature for 5 min. 
At the same time，a microsample plate of which four wells were labelled with 
‘A，'T' ‘C，‘G, was prepared for labeling reaction. First, 2.5 ^1 of each ‘A，，'T', ‘C，， 
‘G，mix short (mixture of nucleotides) were added to the four labelled welIs, the plate 
was warmed at 37°C for more than 1 min. Then 4.5 |il of the labelled mixture was 
transferred into each of the four pre-warmed wells containing the 'A' 'T' 'C' 'G' mix 
short. The components were mixed by gently pipetting and then incubated at 37°C for 5 
min. The reaction was stopped by adding 5 |il stop solution (0.3% bromophenol blue, 
0.3% xylene cyanol FF, 10 mM EDTA, pH 7.5, 97.5% deionized formamide) to the 
mixture. The mixture was then treated to denaturing polyacrylamide gel 
electrophoresis. 
A 6% polyacrylamide gel of 30 x 40 cm was prepared for electrophoresis. When 
the gel was polymerized completely, the glass plates with the gel were attached to a 
electrophoresis apparatus (Owl company, USA), lx Tris-borate/EDTA electrophoresis 
buffer (TBE) was poured to the top and bottom reservoirs and the gel was pre-run at 
constant power (65W, 1900 voltage) for 45 min before loading the sequencing samples. 
The samples were denatured at 80°C for 3 min and 2 |il of the samples were first loaded 
to the gel and run. When the first loading samples migrated to the bottom reservoir, the 
second loading of the sequencing samples was applied to the gel and run. At the end of 
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the electrophoresis, the gel was removed from the apparatus. A piece of Waterman 
3MM paper was placed on the surface of the gel and the gel was attached to the paper 
by applying gentle pressure. The gel was then dried under vacuum on a commercial gel 
dryer system set at 80°C for 90 min. The dried gel was exposed to a X-ray film at room 
temperature for overnight (Kodak, 35 x 43 cm). The autoradiograph was then 
developed. The plasmid DNA sequence was read and compared with the published 
sequence of the rat gonadotropin-releasing hormone gene (GENEBANK, accession 
number M31670; Bond et aL, 1989). 
2.5.7 Southern blot analysis 
2.5.7.1 Southern blotting 
After PCR amplification for the GnRH gene with SF2 and SRi primers coding a 
length of 260 bp, the PCR DNA of the prostate and pituitary samples obtained from the 
different experimental groups were analyzed by Southern blotting. The procedure was 
described as follows: 6^1of the PCR samples were electrophoresed in a 1% agarose gel. 
After electrophoresis, the agarose gel was shaken in a denaturing buffer (0.15M NaCl， 
0.5M NaOH) for 15 min at room temperature and then transferred to a neutralization 
buffer (0.5 M Tris-HCl, pH 7.2’ 1.5M NaCl, 0.1 mM EDTA) for 15 min at room 
temperature with 2 changes. After neutralization, the DNA product from the gel was 
transblotted onto the nylon membrane (Hybond-N, Amersham，USA) with 20 x SSC 
buffer (3M NaCl, 0.3M sodium citrate) by a capillary diffusion method (Khandjian, 
1987) . After capillary transfer, the nylon membrane was washed with 2x SSC buffer to 
remove the adhered agarose gel and dried at 60°C for 10 min. The transblotted DNA 
was crosslinked to the membrane by exposure to 254 nm wavelength ultraviolet light 
(UV Crosslinker, Amersham, USA) for 5 min. 
2.5.7.2 Preparation ofa-^^P-dCTP labelled GnRHprobe 
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The GnRH cDNA fragment inserted in the pSK plasmid was amplified by PCR 
for 30 cycles using the sense SF2 and the antisence SR2 primers. The plasmid carrying 
the inserted GnRH cDNA was used as the PCR template. The PCR DNA product was 
separated in a 1% agarose gel electrophoresis and the cDNA with the right size (230 bp) 
was extracted by using a Sephaglas BandPrep Kit (Pharmacia Biotech) as described in 
section 2.5.4. The amount ofDNA was quantified by measuring its absorbance at 260 
nm. 
The amplified GnRH cDNA by PCR was labelled with a-32p-dCTP by random 
primer labeling method (Feinberg et al., 1983) using a Rad Prime DNA Labeling 
System kit (GibcoBRL, USA). The cDNA (10 i^l containing 50 ng DNA) was first 
denatured at 100�C in boiling water for 5 min. The labeling reaction mixture was 
prepared as follows: 20 ^1 of the 2.5 x Random Primer solution (125 mM Tris-HCI, pH 
6.8; 12.5 mM MgCl2; 25mM 2-mercaptoethanol; 150 jig/ml oligodeoxyribonucleotide 
primer)，each of 1 i^l of 10 nM dATP, dTTP and dGTP, 5 ^1 of a-32p-dCTP 
(3000ci/nmol, 10 fici^d，Amersham), 10 i^l of denatured cDNA, 9 ^1 of distilled water 
and 1 nl of Klenow Fragment polymerase (40U) were mixed. The mixture was 
incubated at 37�C for 30 min. The reaction was stopped by adding 5 i^l ofstop solution 
(0.2 M EDTA) to the mixture. 
2.5.7.5 Hybridization 
The nylon membrane with the transblotted DNA was prehybridized with pre-
hybridization solution (6.25 ml 20 x SSC, 2.5 ml 50 x Denhardt's solution, 1.25 ml 10% 
SDS, 0.5 mg calf thymus DNA) at 65�C for 60 min. After pre-hybridization, 50 ^1 of 
the denatured 32p_iabelled GnRH cDNA probe was added to the prehybrization 
solution, the membrane was further hybridized at 65�C ovemight. After hybridization, 
the membrane was first washed with 2 x SSC with 0.1% SDS at room temperature for 
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10 min, then washed with 1 x SSC and 0.1% SDS for 15 min at 65°C, finally washed 
with 0.1 X SSC and 0.1 % SDS at 65�C for 10 min. For autoradiography, the membrane 
was exposed to x-ray film at -70°C for 2 min to 24 hours. 
2.6 Detection of mRNA expression of gonadotropin-releasing 
hormone receptor (GnRH-R) in normal and neoplastic rat 
prostates 
The strategy that was used to detect the mRNA expression of GnRH-R in rat 
prostates was to clone a GnRH-R cDNA fragment from the rat pituitary gland and then 
use the cloned cDNA to synthesize a specific GnRH-R probe to detect its expression in 
the normal and neoplastic rat prostates. The cDNA obtained from the normal Noble rat 
pituitary gland was amplified by three pairs of primers specific for GnRH receptor gene 
by PCR. The DNA amplified by the PCR was used for subcloning followed by DNA 
sequencing to confirm with the published sequence of the rat GnRH-R gene. Therefore, 
the plasmid containing the cDNA fragment of GnRH receptor was cloned and following 
the procedure as described in sections 2.5.4 to 2.5.6. The DNA of the GnRH receptor 
was labelled with 32p_dCTP and the probe generated was then used to detect the 
mRNA expression of GnRH-R in normal and neoplastic prostates by Southern blot 
analysis. 
2.6.1 Cloning of GnRH-R cDNA and synthesis of its probe from the 
normal Noble rat pituitary 
The cDNA obtained from the normal Noble rat pituitary gland was used for 
PCR amplification of the gene expression of GnRH receptor. Three pairs of primers 
were designed according to the published cDNA sequence of the rat GnRH receptor 
mRNA (GENEBANK，accession number L25053; Perrin et aL’ 1993 and shown in Fig. 
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20). The three pairs of primers used for GnRH-R amplification have the following 
sequences: 
a. The first pair of primers codes a length of 539 bp DNA fragment: 
sense primer: 
rSF2: 5，CCA GCC TTC ATG ATG GTG GTG A 3， 
antisense primer: 
rSR2: 3’ TTG ACT GGC TCT GAC ACC CTG 5’ 
The second pair of primers codes a length of 371 bp DNA fragment: 
sense primer: 
rSF2: 5，CCA GCC TTC ATG ATG GTG GTG A 3， 
antisense primer: 
sp734R: 3，ATT CAG CTG TAG TTT GCG TGG 5， 
The third pair of primers codes a length of 340 bp DNA fragment 
sense primer: 
rSF 1: 5 ’ GAT CGC TCC CTG GCC GTC AC 3 ’ 
antisense primer: 
sp734R: 3' ATT CAG CTG TAG TTT GCG TGG 5， 
The cDNA obtained from the normal Noble rat pituitary gland was first 
amplified by the rSF2 and rSR2 primers which code a length of539 bp DNA fragment 
of GnRH-R. The first PCR product was then used as the DNA template for the second 
PCR amplification using the rSF2 and sp734R primers to further amplify a 380 bp DNA 
fragment of GnRH-R. The other set of PCR reaction was also performed: the pituitary 
gland cDNA was first amplified by the rSF2 and sp734R primers, it was followed by a 
second PCR using the rSFj and sp734R primers which would fmally amplify a 340 bp 
DNA fragment of GnRH-R. The PCR products amplified by the two PCR reactions 
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were electrophoresed in a 1% agarose gel. The cDNA fragment with the correct size 
(i.e. 371 bp or 340 bp) were extracted and purified from the agarose gel. The extracted 
cDNA fragments were separated for a second time in 1% agarose and then were 
subcloned into the pSK vector, following the procedure as described in sections 2.5.4 
to 2.5.6. The plasmids carrying the cDNA fragment of GnRH-R were transformed into 
the E.coli competent cells and allowed to grow. The plasmids were used for nucleotide 
sequencing to confirm the DNA sequence of the inserted cDNA with the known 
sequence of the GnRH-R gene. 
The plasmid containing the inserted GnRH receptor cDNA fragment are used to 
synthesize a specific DNA probe for GnRH receptor. The plasmids were first amplified 
by PCR using rSFi and sp734R primers. The cDNA was purified and labelled with the 
a-32p-dCTP for subsequent Southern blot analysis. 
2.6.2 Detection of GnRH receptor mRNA expression in normal and 
dysplastic Noble rat prostates by southern blot 
The GnRH receptor mRNA expression was detected by two methodologies: 
a 
amplification of the mRNA by RT-PCR followed by Southern blot analysis using a 
DNA probe specific for GnRH receptor gene. The cDNA samples obtained from 
prostates of normal Noble rats and Noble rats treated with T+E2 or T+DES for 9 
months were amplified by the two pairs of primers: rSF2 and rSR2, rSFi and sp734R, 
respectively. In the first PCR experiment, the PCR products amplified by two PCR 
reactions using rSF2 and rSR2 primers were electrophoresed in a 1% agarose gel and 
then transblotted onto nylon membranes. The nylon membranes with the transblotted 
DNA were then hybridized with the GnRH receptor probe labelled with a-32p_dCTP. 
In the second PCR experiment, two continuous PCR reactions were performed. After 
the first PCR with the primers rSF2 and rSR2, the DNA products were further amplified 
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by a second PCR with another pair of primers rSFi and sp734R. The DNA products 
were analyzed by agarose gel electrophoresis. 
2.6.3 Detection of GnRH receptor mRNA expression in Dunning tumor 
Similar to the procedure used for PCR amplification of the GnRH receptor 
mRNA in the pituitary gland, the cDNA obtained from the Dunning tumor was 
amplified by one PCR reaction using separately three pairs of primers: rSF2 and rSR2, 
rSF2 and sp734R, rSFi and sp734R. The DNA products amplified by three different 
pairs of primers were then transblotted onto nylon membrane and hybridized with the 
GnRH receptor DNA probe by southern blot analysis as described in sections 2.5.7.1 to 
2.5.7.3. In the second PCR experiment, two continuous PCR reactions were performed. 
The DNA products amplified by the first PCR using rSF2 and sp734R primers were 
further amplified by a second PCR using rSFj and sp734R primers which codes a 
length of 340 bp cDNA fragment of GnRH receptor mRNA. In order to confirm the 
DNA sequence of the PCR products, the PCR products were extracted from the agarose 
gel for subcloning following by DNA sequencing as described in sections 2.5.4 to 2.5.6. 
2.6.4 Detection of the GnRH receptor mRNA expression in AIT tumor 
byRT-PCR 
The cDNA obtained form the AIT tumor was first amplified by a PCR reaction 
using the rSF2 and sp734R primers followed by a second PCR amplified by the rSFj 
and sp734R primers. The PCR products were analyzed by the agarose electrophoresis to 
confirm their sizes. 
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Chapter 3. Results 
3.1 Detection of mRNA expression of gonadotropin-releasing 
hormone (GnRH) in normal and neoplastic rat prostates 
3.1.1 Reverse transcription polymerase chain reaction (RT-PCR) 
The expression of gonadotropin-releasing hormone in normal and neoplastic rat 
prostates was detected and analyzed by RT-PCR. The structure of the rat GnRH gene 
and the fragment of nucleotides amplified by PCR are illustrated in figure 1 (p.47). The 
cDNA samples obtained from different experimental groups were first amplified with 
the SF2 and SR] primers which code a length of 263 bpDNA fragment of the GnRH 
gene or its mRNA. Except the AIT sample, all samples demonstrated a band with the 
size of 263 bp which corresponds to the GnRH gene amplified by the SF2 and SR\ 
primers (Figs. 2-8). 
After the first PCR amplification, the PCR products from the ventral prostate of 
the normal Noble rat, rat Dunning tumor and AIT were used as templates and further 
amplify a second PCR using another pair of primers (SF2 and SR2) which code a length 
of 230 bp DNA fragment of GnRH gene. After the second PCR, samples gave two 
bands: the large band had a size of263 bp, the small band had a size of230 bp (Figs. 9-
10). These PCR products corresponded to the GnRH gene amplified by the two pairs of 
primers: SF2 and SRi (263 bp), SF2 and SR2 (230 bp). The other bands obtained from 
the second PCR were the non-specific bands due to non specific priming. 
3.1.2 Purification of DNA fragments amplified by PCR from the 
agarose gel 
The DNA fragments with a correct size of 230 bp obtained from the samples of 
normal ventral prostate, Dunning prostatic tumor and AIT tumor after second PCR 
amplification were extracted and purified from the agarose gel. The extracted DNA 
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products were then eIectrophoresed and analyzed again in 1% agarose gel. All DNA 
samples showed a correct size of 230 bp which confirmed with the size of the second 
PCR product after purification and agarose gel electrophoresis (Figs. 11-12). 
3.L3 Subcloning of DNA into vector 
The extracted DNAs was first ligated with the linearized pBluescript SK vector. 
The pSK plasmids were then transformed into XL-I blue E.coli competent cells. The 
E.coli competent cells were grown in agar plate which contained the x-gaI and IPTG for 
/ac-selection. Two kinds of colonies were seen in the plates: the white-colored colonies 
were recombinants and the blue-colored colonies were untransformed non-
recombinants. The white-colored colonies were then picked up and further grown in the 
LB medium for subsequent small-scale extraction of plasmids. The extracted plasmids 
were analyzed by digestion with restriction enzymes BamH I and EcoR I. The digested 
products showed fragments of two sizes. One DNA fragment showed a size of2.96 kb 
which is same as the length of pSK vector, while the other fragment showed a size of 
230 bp which corresponded to GnRH mRNA amplified by SF2 and SR2 primers after 
the second PCR (Figs. 13-15). 
3.1.4 Nucleotide sequencing 
The nucleotide sequences of the plasmid DNAs obtained from the subcloned 
GnRH cDNAs of the normal Noble rat ventral prostate, rat Dunning tumor and AIT 
tumor are shown in figure 16 and the nucleotide sequence matched with the published 
sequence of the rat gonadotropin-releasing hormone gene (GENEBANK, accession 
number M31670; Bond et al., 1989). 
3.L5 Southern blot analysis 
The cDNAs obtained from different organs (including pituitary gland, ventral 
prostate, dorsal prostate, lateral prostate, coagulating gland and seminal vesicle) of the 
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normal Noble rat, ventral prostate, dorsal prostate and lateral prostate of Noble rats 
treated with T+E2 or T+DES for 4 or 9 months, rat Dunning tumor and AIT were used 
to amplify the GnRH gene with SF2 and SR\ primers which code a length of 263 bp 
DNA fragment. The PCR products were separated by 1% agarose gel electrophoresis. 
Except the AIT sample, all cDNA samples gave a specific band with a size of 263 bp 
(Figs. 17a and 18a). The PCR DNA products were then transblotted onto nylon 
membrane for subsequent Southern-blotting, using a a-32p_dCTP labelled GnRH probe 
which codes a size of 230 bp of GnRH mRNA (Fig. 1). The results o f the Southern-
blotting are shown in Figure 17b and 18b. All samples, except the AIT sample, showed 
a hybridization band with the GnRH probe after 2-min exposure to x-ray film. 
However, when the membranes were allowed to expose to x-ray film for 24 hours, the 
AIT sample showed a hybridization band (Fig. 19) 
3.2 Detection of gonadotropin-releasing hormone receptor mRNA 
expression in normal and neoplastic rat prostates 
3'2.1 Cloning of gonadotropin-releasing hormone receptor (GnRH-R) 
cDNA and synthesis of its probe from the normal Noble rat 
pituitary gland 
The molecular size (2938 bp) of the GnRH receptor mRNA and the 
combination use of the pairs of primers to amplify its mRNA from the pituitary gland 
cDNA are shown in Figure 20. The cDNA obtained from the pituitary gland was used to 
amplified the GnRH receptor mRNA with rSF2 and rSR2 primers and resulted in a 
band with a size of 539 bp (Lane 3 in Fig. 21). PCR DNA product was used as the 
template for the second PCR to further amplify the GnRH receptor DNA fragment with 
another pair of primers (rSF2 and sp734R). The second PCR amplification gave band 
with a size of 380 bp (Lane 2 in Fig. 22). The other set of PCR experiment was also 
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performed: the pituitary cDNA was amplified by the first PCR using rSF2 and sp734R 
primers and resulted in a band with a size of 371 bp (Lane 2 in Fig. 21). The first PCR 
product was used as the template to further amplify by a second PCR using another pair 
of primers (rSFi and sp734R) and resulted in a strong band with a size of340 bp (Lane 
1 in Fig. 22). The cDNA fragments with sizes of 371 and 340 bp respectively of the 
GnRH receptor mRNA from the rat pituitary gland ampHfied by two different sets of 
PCR reaction were extracted from the gels and further separated in 1% agarose gel 
electrophoresis (Fig. 23). These two GnRH receptor cDNA fragments were then used to 
subclone into pSK vector. The plasmids carrying the inserted GnRH receptor cDNA 
fragments were analyzed by digestion with restriction enzymes BamH I and EcoR I in 
order to confirm the correct sizes of the inserted cDNA fragment. The plasmids 
containing the 340 bp cDNA fragments showed two sizes of fragments after restriction 
enzyme digestion. The larger fragment with a size of2.96 kb was identical to the length 
ofpSK vector. The smaller fragment with a size of 340 bp corresponded to the GnRH 
receptor cDNA amplified by rSF] and sp734R primers (Fig. 24). The plasmids 
containing the 371 bp cDNA fragment also showed two sizes of fragments after 
restriction enzyme digestion. Similarly the larger fragment with a size of 2.96 kb 
represented the length of pSK vector, whereas the smaller fragment with a size of380 
bp represented the GnRH receptor cDNA amplified by the rSF2 and sp734R primers 
(Fig. 25). The plasmids containing the inserted GnRH receptor cDNAs with correct size 
were used for DNA sequencing in order to confirm the DNA sequence with the 
published data. The results of the DNA sequence of these two GnRH receptor cDNA 
fragments are listed in Figures 26 and 27，and the DNA sequence completely matched 
with the published sequence of the rat GnRH receptor mRNA. The plasmids containing 
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the inserted 340 bp cDNA were used to synthesize a a-32p-dCTP labelled probe 
specific for rat GnRH-receptor for subsequent Southern blot analysis. 
3.2.2 Detection of GnRH receptor mRNA expression in normal and 
dysplastic Noble rat prostates by Southern blotting andPCR 
The cDNAs, obtained from the individual lobes of prostate gland and the 
pituitary gland of the normal intact Noble rats as well as rats which had been treated 
with either T+E2 or T+DES for 9 months were first amplify by a PCR reaction using 
rSF2 and rSR2 primers in order to amplify any GnRH receptor mRNA signals in these 
tissues. The result of the PCR amplification of the pituitary gland samples taken from 
the normal, T+E2 and T+DES treated Noble rats demonstrated a band with a size of 
539 bp which represented the amplified GnRH receptor gene. However, no bands were 
observed in the prostate samples taken from the normal, T+E2 and T+DES treated rats 
after PCR amplification (Fig 28a-30a). The DNA products after the PCR amplification 
were transblotted onto nylon membranes for subsequent Southern blot analysis using a 
specific probe for GnRH receptor generated from the pituitary gland as described in 
previous section 3.2.1 and Figs. 24 and 25. Only the samples from the normal and 
hormone-treated pituitary gland showed a strong hybridization band with the GnRH 
receptor probe. However, samples from the normal and hormone-treated prostates 
showed negative results with the probe (Fig. 28b-30b). 
Another approach to detect the GnRH receptor mRNA expression in the 
prostate and pituitary gland samples obtained from the normal and hormone-treated rats 
was to amplify the mRNA signal by two PCR reactions using two pairs ofprimers. The 
first PCR was amplified by the rSF2 and rSR2 primers followed by a second PCR 
reaction with another pair of primers (rSF] and sp734R). The results showed that only 
the samples of pituitary gland obtained from either normal or hormone-treated rats 
demonstrated a band with the correct size of 340 bp amplified by the rSF] and sp734R 
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primers, whereas no signal was obtained in the samples ofprostate glands (Figs. 31-32). 
The results of both Southern blotting and PCR suggested that GnRH receptor is not 
expressed in the normal and dysplastic rat prostates. 
3丄3 Detection of GnRH receptor mRNA expression in rat Dunning 
tumor by PCR 
The GnRH receptor mRNA expression in the cDNA sample ofthe rat Dunning 
tumor was detected by PCR using three different pairs ofprimers: rSF2 and rSR2, rSF2 
and sp734R, rSFi and sp734R (shown in Fig. 20). No signals were detected in the 
ethidium bromide-gel after the single PCR reaction (Fig 33a). The DNA products after 
the first PCR were subsequently transblotted onto nylon membranes for Southern 
blotting hybridizing with a probe (340 bp) specific for the GnRH receptor generated 
from the pituitary gland. The results showed that the tumor sample amplified by the 
rSFi and sp734R primers demonstrated a hybridization signal with the GnRH receptor 
probe (lane 3 in Fig.33b). However, no hybridization signals were seen in the tumor 
sample amplified by other two pairs of primers. 
To confirm the positive expression of GnRH receptor in the Dunning tumor, the 
tumor cDNA sample was amplified twice by two PCRs using rSF2 and sp734R, then 
rSFi and sp734R primers. After the second PCR amplification, a strong band with the 
correct size of 340 bp was seen (Fig. 34). This 340 bp cDNA fragment was then 
extracted and used for subcloning and DNA sequencing. The sequence data showed that 
this 340 bp DNA fragment matched completely with the published sequence of the 
GnRH receptor mRNA (Fig. 35). 
3.2.4 Detection of GnRH receptor mRNA expression in AIT 
The mRNA expression of GnRH receptor in AIT tumor was detected by two 
PCR amplification. The first PCR was amplified by rSF2 and sp734R primers. It was 
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then followed by a second PCR using the first PCR DNA products as the template and 
another pair of primers (rSF2 and sp734R). However, no specific bands with the correct 
size of340 bp were detected after second PCR amplification (Fig 36-37). 
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Figure 1. The structure of the rat GnRH gene and the nucleotide fragment amplified by 
PCR. 
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Figure 2. The result ofthe PCR using the SF2 and SRi primers to amplified the GnRH 
mRNA expression in normal prostate gland. The cDNAs were obtained from 
the individual lobes of the prostate gland, pituitary and hypothalamus of the 
normal Noble rat. Lane 1 = the negative control which has the same condition 
as other samples, but without any cDNA template; lane 2 = ventral prostate; 
lane 3 = dorsal prostate; lane 4 =lateral prostate; lane 5 = pituitary gland; lane 
6 = hypothalamus. The bands obtained in lanes 2-6 have a size of 263 bp 
which corresponds to the GnRH mRNA expression. 
Figure 3. The result of the PCR using the SF2 and SR4 primers to amplify the GnRH 
mRNA expression in coagulating gland and seminal vesicle. The cDNAs 
were obtained from the normal Noble rats. Lane 1 = the negative control 
without cDNA template; Lane 2 = the coagulating gland; Lane 3 = seminal 
vesicles. The bands obtained from lanes 2 and 3 have a size of 263 bp which 
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Figure 4. The result of the PCR to amplify the GnRH mRNA expression in T+E2 
treated prostate gland using SF2 and SK\ primers. The cDNAs were 
obtained from the individual lobes of prostate gland and pituitary gland of 
the Noble rats which have been treated with T+E2 for 4 months. Lane = is 
the negative control; Lane 2 =ventraI prostate; lane 3 =dorsal prostate; lane 
4 =lateral prostate; lane 5 =pituitary. The bands obtained in lanes 2-5 show 
a size of 263 bp which corresponds correctly to the amplified GnRH 
mRNA. 
Figure 5. The result of the PCR to amplify the GnRH mRNA expression in the T+E2 
treated prostate gland using SF2 and SRi primers. The cDNAs were 
obtained from the different lobes of the prostate gland and pituitary of the 
Noble rats which have been treated with T+E2 for 9 months. Lane 1 = 
ventral prostate; lane 2 = dorsal prostate; lane 3 = lateral prostate; lane 4 = 
hypothalamus; lane 5 = pituitary. The bands in the lanes 1-5 with a size of 
263 bp correspond to the GnRH mRNA expression. The other bands in 
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Figure 6. The result of the PCR to amplify the GnRH mRNA expression in T+DES 
treated prostate gland using SF2 and SRj primers. The cDNAs were 
obtained from the different prostatic lobes and pituitary of the Noble rats 
which have been treated with T+DES for 4 months. Lane 1 = the negative 
control; lane 2 = ventral prostate; lane 3 = dorsal prostate; lane 4 = lateral 
prostate; lane 5 = pituitary. The bands obtained in lanes 2-5 show a correct 
size of 263 bp which corresponds to the GnRH mRNA. 
Figure 7. The result ofthe PCR to amplify the GnRH mRNA expression in the T+DES 
treated prostate gland using SF2 and SR\ primers. The cDNAs were 
obtained from the different prostatic lobes and pituitary of the Noble rats 
which have been treated with T+DES for 9 months. Lane 1 = negative 
control; Lane 2 = ventral prostate; lane 3 = dorsal prostate; lane 4 = lateral 
prostate; lane 5 = pituitary. The bands obtained in lanes 2-5 show a correct 
size of 263 bp which corresponds to the GnRH mRNA. 
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Figure 8. The result of the PCR to amplify the GnRH mRNA expression in rat Dunning 
prostatic tumor and AIT tumor using SF2 and SR\ primers. Lane 1 = 
negative control; lane 2 = AIT; lane 3 = rat Dunning tumor. The band 
obtained in Iane 3 shows a correct size of 263 bp which corresponds to the 
GnRH gene. No band is observed in the lanes 1 and 2. 
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Figure 9. The result of the second PCR which further amplifies the GnRH mRNA 
expression in the normal ventral prostate using the first PCR DNA product as 
template and SF2 and SR2 primers. The DNA template used for the second 
PCR was obtained first PCR product of the normal ventral prostate after 
GnRH mRNA amplification. Lane 1 = negative control without DNA; lane 2 
=ventral prostate. Two bands were obtained in lane 2: the larger band with a 
size of 263 bp represents the GnRH mRNA amplified by SF2 and SR\ 
primers; the smaller band with a size of 230 bp represents the GnRH mRNA 
amplified by SF2 and SR2 primers. 
Figure 10. The result of the second PCR which further amplified the GnRH mRNA 
expression in the rat Dunning prostatic tumor and AIT tumor. The DNA 
template used for the second PCR was obtained from the first PCR product 
of the Dunning tumor and AIT tumor after GnRH mRNA amplification. 
Lane 1 = negative control; lane 2 = AIT; lane 3 = Dunning prostatic tumor. 
Two strong bands are seen in lane 2 and 3: the larger band with a size of 263 
bp represents the GnRH mRNA amplified by SF2 and SRj primers; whereas 
the smaller band with a size of 230 bp represents the GnRH mRNA 
amplified by SF2 and SR2 primers.The other bands seen in lane 2 and 3 
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Figure 11. The purified DNA product obtained from the normal Noble rat ventral 
prostate after the second PCR amplification prostate shows a size of 230 
bp. 
Figure 12. The purified DNA products obtained from both Dunning prostatic tumor 
(Lane 1) and AIT (Lane 2) after the second PCR amplification shows a size 
of230bp. 
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Figure 13. Digestion of the plasmids with the inserted GnRH cDNA by restriction 
enzymes BamH I and EcoR I. The inserted cDNA (230 bp) samples were 
obtained from the normal Noble rat ventral prostate amplified by two PCR 
reactions. Two bands are seen in the agarose gel: the larger bands with a 
size of2.96 kb corresponds to the whole length of the pSK vector, whereas 
the smaller bands with a size of 230 bp corresponds to the inserted GnRH 
cDNA. The different lanes represent the plasmids extracted from different 
recombinant colonies. 
Figure 14. Similar digestion of the plasmids with restriction enzymes BamH I and EcoR 
I. The plasmids containing the inserted cDNA were obtained from the rat 
Dunning tumor samples after two PCR amplifications. The larger bands with 
a size of 2.96 kb correspond to the length of the pSK vector, whereas the 
smaller bands with a size of230 bp correspond to the inserted GnRH cDNA. 
Figure 15. Digestion of the plasmids, which contain the inserted cDNA obtained from 
the AIT samples with restriction enzymes Bam HI and Eco RI. Similarly, 
the larger bands with a size of 2.96 kb correspond to the length of the pSK 
vector, whereas the smaller bands with a size of 230 bp corresponds to the 













 1 1 s 
• 
^ ^ ^ ^ ^ B
 _ S 5 P < P > ^ P ^ U ^ ^ S












Figure 16. The sequence map of the cDNA fragment of the GnRH gene amplified by 
SF2 and SR2 primers obtained from the sample of the normal Noble rat 
ventral prostate, rat Dunning tumor and AIT tumor. 
I SF2 > I 
5，G A A A C G A T G C C C A A A C T G A T G G C C G C T G T T G T T C T G T T G A C T G T G 
TGT TTG GAA GGC TGC TCC AGC CAG CAC TGG TCC TAT GGG TTG CGC 
CCT GGG GGG AAG AGA AAT ACT GAA CAC TTG GTT GAT TCT TTC CAA 
GAG ATG GGC AAG GAG GAG GAT CAA ATG GCA GAA CCC CAG AAC TTC 
GAA TGC ACT GTC CAC TGG CCC CGT TCA CCT CTT AGG GAT CTG CGA 
GGA GC 3， I sR2  
5 3 
Figure 17a. All cDNA samples gave bands with a size of 230 bp which correspond to 
the GnRH mRNA amplified by PCR using SF2 and SRi primers. The 
amplified PCR DNA products were then analyzed by subsequent 
Southern-blotting as shown in Fig. 17b. Lane 1 = the negative control 
without cDNA; lanes 2-7 represent the cDNA samples obtained 
respectively from pituitary gland, ventral prostate, dorsal prostate, lateral 
prostate, coagulating gland and seminal vesicles of the normal intact 
Noble rat; lanes 8-10 represent the samples of ventral prostate, dorsal 
prostate and lateral prostate obtained from the Noble rats treated with 
T+E2 for 4 months; lanes 11-12 represent the samples of ventral prostate 
and dorsal prostate obtained from the Noble rats treated with T+E2 for 9 
months. 
Figure 17b. The result ofthe Southern blotting of the PCR DNA products obtained from 
different organs shows a hybridization band with the a-32p-dCTP 
labelled GnRH probe. Lane 1 = the negative control without cDNA; lanes 
2-7 represent the cDNA samples obtained respectively from pituitary 
gland, ventral prostate, dorsal prostate, lateral prostate, coagulating gland 
and seminal vesicles of the normal intact Noble rat; lanes 8-10 represent 
the samples of ventral prostate, dorsal prostate and lateral prostate 
obtained from the Noble rats treated with T+E2 for 4 months; lanes 11-12 
represent the samples of ventral prostate and dorsal prostate obtained from 
the Noble rats treated with T+E2 for 9 months. 
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Figure 18a. The result of the PCR amplified by SF2 and SR\ primers and the PCR 
DNA products were then analyzed by Southern blotting. All samples, 
except the AIT samples (lane 9)，gave a band with 263 bp which 
corresponds to the GnRH gene amplified by SF2 and SR\ primers. Land 1 
is the cDNA sample of lateral prostate obtained from the Noble rats treated 
with T+E2 for 9 months; lane 2-4 are the samples of ventral prostate, 
dorsal prostate and lateral prostate obtained from the Noble rat treated with 
T+DES for 4 months; lane 5-7 are the samples of ventral prostate, dorsal 
prostate and lateral prostate obtained from the Noble rat treated with 
T+DES for 9 months; lane 8 is the sample from rat Dunning tumor; lane 9 
is AIT sample. 
Figure 18b. The result of the Southern blotting after 2 min exposure to x-ray film for 
autoradiography. All cDNA samples, except the AIT sample (lane 9)，show 
a hybridization band with the GnRH probe (230 bp). Land 1 is the cDNA 
sample of lateral prostate obtained from the Noble rats treated with T+E2 
for 9 months; lane 2-4 are the samples of ventral prostate, dorsal prostate 
and lateral prostate obtained from the Noble rats treated with T+DES for 4 
months; lane 5-7 are the samples of ventral prostate, dorsal prostate and 
lateral prostate obtained from the Noble rats treated with T+DES for 9 
months; lane 8 is the sample from rat Dunning tumor. 
Figure 19. Southern blot of the AIT sample (lane 9) after 24-hour exposure to x-ray 
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Figure 20. The molecular size of the GnRH receptor mRNA and the sets of primers 
used to amplify its mRNA from the pituitary gland cDNA were shown. The 
cDNA fragment amplified by rSFi and sp734R primers is then subcloned 
into pSK vector and the clone thus obtained is used to synthesize a cDNA 
probe (340 bp) specific for GnRH receptor mRNA. 
GnRH receptor mRNA 
2938 bp 
rSF2 rSFl 
~ • — > 
—— LT -, j ' ^ ' ^ 八 
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rSFl 
probe _ _ ^ 




Figure 21. Result ofthe first PCR reaction amplifying the GnRH receptor mRNA from 
the rat pituitary gland cDNA. Lane 1 is the negative control without 
pituitary gland cDNA; lane 2 represents the result ofPCR using the pituitary 
cDNA obtained from the normal Noble rat using rSF2 and sp734R primers 
which amplify a band of 371 bp; lane 3 represents the result of PCR using 
pituitary cDNA together with rSF2 and rSR2 primers which amplify a band 
of539bp. 
Figure 22. Result of the second PCR reaction to further amplify the GnRH receptor 
mRNA from the rat pituitary gland using the first PCR DNA product as 
templates. Lane 1 shows the result of the second PCR which used the first 
PCR product (371 bp DNA fragment amplified by rSF2 and sp734R 
primers) as template with another pair of primers (rSFi and sp734R), and 
resulted in a strong band of 340 bp. Lane 2 shows the result of the second 
PCR which uses the first PCR product (539 bp DNA fragment amplified by 
rSF2 and rSR2 primers) as template and amplified with rSF2 and sp734R 
primers, and resulted in a strong band of 371 bp. The other bands observed 
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Figure 23. Further purification and separation of cDNA fragment of the GnRH receptor 
mRNA from the rat pituitary gland after two different sets of PCR reactions 
by 1% agarose gel electrophoresis. Lane 1 shows a cDNA fragment with a 
size of 340 bp (amplified first by rsF2 and sp734R followed by a second 
PCR with rSFi and sp734R primers). Lane 2 shows a cDNA fragment with 
size of371 bp (amplified by rSF2 and rSR2 followed by a second PCR with 
rsF2 and sp734R primers). The different combination use of primer sets are 
illustrated in Figure 21. The purified cDNA fragments (340 bp and 371 bp) 
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Figure 24. Analysis ofthe plasmids with the inserted 340 bp cDNA fragment of GnRH 
receptor by digestion with restriction enzymes BamYi I and EcoR I. The 
inserted 340 bp cDNA fragment represents the result of the second PCR 
amplified with rSFi and sp734R primers as shown in Figs 21 and 22. Note 
that the intensities of the larger bands with a size of 2.96 kb represent the 
whole length of the pSK vector. Whereas the smaller bands with a size of 
340 bp represent the inserted cDNA fragment of the GnRH receptor mRNA. 
The different lanes represent the different representative clones created by 
the subcloning. 
Figure 25. Similar analysis of the plasmids with the inserted 371 bp cDNA fragment of 
GnRH receptor mRNA by digestion with restriction enzymes BamH I and 
EcoR I. The inserted 371 bp cDNA fragment represents the result of the 
second PCR amplified with rSF2 and sp734R primers as shown in Fig. 21 
and 22. Similarly, the larger bands with a size of 2.96 kb represent the whole 
length of the pSK vector, whereas the smaller bands with a size of 380 bp 
represent the inserted cDNA fragment of the GnRH receptor mRNA. The 
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Figure 26. The sequence map of the 371 bp cDNA fragment ofthe GnRH receptor gene 
obtained from the pituitary gland of the normal Noble rat amplified with 
rSF2 and sp734R primers. 
I rSF2 > I 
5， CCA GCC TTC ATG ATG GTG GTG ATT AGC CTG GAT CGC TCC CTG 
GCC GTC ACT CAG CCC TTA GCT GTC CAA AGC AAG AGC AAG CTT GAA 
CGG TCT ATG ACC AGC CTG GCC TGG ATT CTC AGC ATT GTC TTT GCG 
GGA CCA CAG TTA TAT ATC TTC AGG ATG ATC TAC CTA GCC GAC GGC 
TCT GGG CCA GCA GTT TTC TCG CAA TGT GTG ACC CAC TGC AGC TTT 
CCG CAA TGG TGG CAT GAA GCC TTC TAC AAC TTT TTC ACC TTC AGC 
TGC CTG TTC ATC ATC CCT CTT CTC ATC ATG CTA ATC TGC AAT GCC 
AAA ATC ATC TTC GCC CTC ACA CGA GTC CTT CAT CAG GAC CCA CGC 
AAA CTA CAG CTG AAT 3’ 
—sp734R  
6 0 
Hgure 27. The sequence map of the 340 bp cDNA fragment of the GnRH receptor 
gene obtained from the pituitary gland of the normal Noble rat amplified 
with rSFi and sp734R primers. 
rSFi > 
5 ， G A T CGC TCC CTG GCC GTC ACT CAG CCC TTA GCT GTC CAA AGC 
AAG AGC AAG CTT GAA CGG TCT ATG ACC AGC CTG GCC TGG ATT CTC 
AGC ATT GTC TTT GCG GGA CCA CAG TTA TAT ATC TTC AGG ATG ATC 
TAC CTA GCC GAC GGC TCT GGG CCA GCA GTT TTC TCG CAA TGT GTG 
ACC CAC TGC AGC TTT CCG CAA TGG TGG CAT GAA GCC TTC TAC AAC 
TTT TTC ACC TTC AGC TGC CTG TTC ATC ATC CCT CTT CTC ATC ATG CTA 
ATC TGC AAT GCC AAA ATC ATC TTC GCC CTC ACA CGA GTC CTT CAT 
CAG GAC CCA CGC AAA CTA CAG CTG AAT 3， 
< sp734R > 
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Figure 28a. The PCR amplification ofany GnRH receptor mRNA expression in cDNA 
samples of normal Noble rat prostates and pituitary gland with rSF2 and 
rSR2 primers. Lane 1 is the negative control which has the same condition 
as the other samples, but without any cDNA template; lane 2 is ventral 
prostate; lane 3 is dorsal prostate; lane 4 is lateral prostate; lane 5 is 
pituitary gland which shows a strong band of 539 bp representing the 
amplified GnRH receptor gene. 
Figure 28b. The Southern blots of the PCR DNA products amplified for the GnRH 
receptor mRNA expression in samples of normal Noble rat prostates and 
pituitary gland as shown in Figure 28a. with a specific GnRH receptor 
probe (340 bp) generated from the pituitary gland (Fig. 23). Lane 1 is the 
negative control; lane 2 is ventral prostate; lane 3 is dorsal prostate; lane 4 
is lateral prostate; lane 5 is pituitary gland of which an intense 
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Figure 29a. The PCR amplification ofany GnRH receptor mRNA expression with rSF2 
and rSR2 primers in cDNA samples obtained from the prostates and 
pituitary gland of the Noble rat treated with T+E2 for 9 months. Lane 1 is 
the negative control; lane 2 is ventral prostate; lane 3 is dorsal prostate; lane 
4 is lateral prostate; lane 5 is pituitary gland which shows a band of 539 bp 
representing the expression of GnRH receptor. 
Figure 29b. The Southern blots of the PCR DNA products after amplification for the 
GnRH receptor mRNA expression in samples of T+E2 treated Noble rat 
prostates and pituitary gland and hybridized with a specific GnRH receptor 
probe (340 bp) generated from the pituitary gland (shown in Fig. 24). Lane 
1 is the negative control; lane 2 is ventral prostate; lane 3 is dorsal prostate; 
lane 4 is lateral prostate; lane 5 is pituitary gland. Similar to Fig 28b.，an 
intense hybridization band with the GnRH receptor probe is seen in lane 5. 
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Figure 30a. The PCR amplification ofany GnRH receptor mRNA expression with rSF2 
and rSR2 primers in cDNA samples obtained from the prostates and 
pituitary gland ofthe Noble rats treated with T+DES for 9 months. Lane 1 
is the negative control; lane 2 is ventral prostate; lane 3 is dorsal prostate; 
lane 4 is lateral prostate; lane 5 is pituitary gland which shows a strong 
band of539 bp representing the expression of GnRH receptor. 
Figure 30b. The Southern blots of the PCR DNA products after amplification for the 
GnRH receptor mRNA expression in samples of T+DES treated Noble rat 
prostates and pituitary gland and hybridized with a specific GnRH receptor 
probe (340 bp) generated from the pituitary gland (shown in Fig. 24). Lane 
1 is the negative control; lane 2 is ventral prostate; lane 3 is dorsal prostate; 
lane 4 is lateral prostate; lane 5 is pituitary gland. Similar to normal and 
T+E2 treated pituitary (Figs. 28b and 29b)，an intense hybridization band 
with the GnRH receptor probe is seen in lane 5. 
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Figure 31. Amplification ofGnRH receptor mRNA expression by two PCR reactions in 
the samples ofnormal and T+E2-treated prostates and pituitaries. The GnRH 
receptor mRNA amplified by the second PCR with rSFi and sp734R primers 
demonstrates a band with a size of 340 bp. Lane 1 and lane 6 are the negative 
controls without DNA template; lanes 2-5 are the samples of ventral prostate, 
dorsal prostate, lateral prostate and pituitary gland obtained from the normal 
intact Noble rats; lanes 7-10 are the samples of ventral prostate, dorsal 
prostate, lateral prostate and pituitary gland obtained from the Noble rats 
treated with T+E2 for 9 months. Only the samples of the pituitary glands 
demonstrates a band with the corrected size of 340 bp as shown in lane 5 and 
10. No specific bands with the correct size were observed in the samples of 
prostates. 
Figure 32. Amplification ofGnRH receptor mRNA expression by two PCR reactions in 
the samples of T+DES treated prostates and pituitary gland. The GnRH 
receptor mRNA amplified by the second PCR with rSFi and sp734R 
primers demonstrates a band with a size of 340 bp. Lane 1 is the negative 
control without DNA template; lanes 2-5 are the samples of ventral prostate, 
dorsal prostate, lateral prostate and pituitary gland obtained from Noble rats 
treated with T+DES for 9 months. Only the sample of pituitary gland gave a 
band of340 bp which corresponds to GnRH receptor mRNA. 
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Figure 33a. Single PCR amplification of GnRH receptor mRNA expression in the 
cDNA sample of the rat Dunning tumor with three different pairs of 
primers. Lane 1 is the tumor sample amplified by rSF2 and rSR2 primers; 
lane 2 is the sample amplified by rSF2 and sp734R primers; lane 3 is the 
sample amplified by rSFj and sp734R primers. No bands were detected in 
the ethidium bromide-stained gels. 
Figure 33b. Southern blotting ofthe PCR DNA products of the Dunning tumor samples 
amplified by three different pairs of primers with a specific probe for GnRH 
receptor generated from the pituitary gland. Lane 1 is the tumor sample 
amplified by rSF2 and rSR2 primers; lane 2 is the sample amplified by rSF2 
and sp734R primers; lane 3 is the sample amplified by rSFi and sp734R 
primers. Tumor sample amplified by rSFi and sp734R primers showed a 
hybridization band with the GnRH receptor probe. 
Figure 34. Double PCR amplification of GnRH receptor mRNA expression in the 
cDNA sample of the rat Dunning tumor with two pairs of primers (rSF2 
and sp734R, rSFi and sp734R). Lane 1 represents the first PCR product 
amplified with rSF2 and sp734R; lane 2 represent the second PCR product 
amplified with rSFi and sp734R. No signal can be observed after the first 
PCR reaction (lane 1). However, a strong band with a size of 340 bp was 
observed after the second PCR (lane 2). 
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Figure 35. The sequence map of the cDNA fragment of the GnRH receptor gene 
obtained from the rat Dunning tumor amplified by the rSFj and sp734R 
primers. 
rSFi > 
5， GAT CGC TCC CTG GCC GTC ACT CAG CCC TTA GCT GTC CAA AGC 
AAG AGC AAG CTT GAA CGG TCT ATG ACC AGC CTG GCC TGG ATT CTC 
AGC ATT GTC TTT GCG GGA CCA CAG TTA TAT ATC TTC AGG ATG ATC 
TAC CTA GCC GAC GGC TCT GGG CCA GCA GTT TTC TCG CAA TGT GTG 
ACC CAC TGC AGC TTT CCG CAA TGG TGG CAT GAA GCC TTC TAC AAC 
TTT TTC ACC TTC AGC TGC CTG TTC ATC ATC CCT CTT CTC ATC ATG CTA 
ATC TGC AAT GCC AAA ATC ATC TTC GCC CTC ACA CGA GTC CTT CAT 
CAG GAC CCA CGC AAA CTA CAG CTG AAT 3， 
< sp734R  
6 7 
Figure 36. First PCR amplification of GnRH receptor mRNA in the AIT tumor using 
rSF2 and sp734R primers. No specific band with size of 371 bp was 
detected. However, non-specific band of about 200 bp was seen. 
Figure 37. Second PCR amplification ofGnRH receptor mRNA in the AIT tumor using 
rSFi and sp734R primers. No specific band with the expected size of 340 
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Chapter 4 Discussion 
4.1. Detection of mRNA expression of gonadotropin-releasing 
hormone (GnRH) in normal and neoplastic rat prostates. 
4.1.1 Expression of GnRH mRNA in normal Noble rat prostate gland. 
The expression of GnRH mRNA in the different lobes of prostate gland 
(including ventral, lateral and dorsal Iobes), coagulating gland, seminal vesicles, 
pituitary gland and hypothalamus was detected and analyzed by reverse-transcription 
polymerase chain reaction (RT-PCR). The cDNA fragments amplified by PCR were 
confirmed to be GnRH by DNA sequencing and Southem-blot hybridization. 
After the first PCR amplification with the SF2 and SRj primers which code a 
length of 263 bp DNA fragment of the GnRH gene or its mRNA, all samples 
demonstrated a band with a size of 263 bp which corresponds to the GnRH gene (Figs. 2 
and 3). The result suggests that GnRH gene may be expressed and synthesized locally in 
the prostate gland, coagulating gland and seminal vesicles, in addition to hypothalamus 
and pituitary gland. No difference in the GnRH expression level was observed in the 
individual lobes of the prostate gland. 
In order to confirm the result and accuracy of the first PCR., the first PCR DNA 
product of the ventral prostate was further amplified by a second PCR using another pair 
of primers (SF2 and SR2) which code a shorter length of 230 bp DNA fragment of the 
GnRH gene or its mRNA. Two bands were observed after the second PCR: the larger 
band showed a size of 263 bp corresponding to GnRH gene amplified by SF2 and SRj 
primers; the smaller band had a size of 230 bp corresponding to GnRH gene amplified 
by SF2 and SR2 primers (Fig. 9). 
The cDNA fragment amplified by PCR was further confirmed to be the GnRH 
gene by DNA sequencing. The cDNA fragment (230 bp) amplified by the second PCR 
6 9 
was extracted and used for subcloning into plasmid vector and analyzed by DNA 
sequencing. Analysis of the DNA sequence showed a complete match with the published 
sequence of ra t gonadotropin-releasing hormone gene (GENEBANK, accession number 
M31670; Bond et al.，1989). The GnRH cDNA clone was then used to synthesize a 
specific DNA probe to confirm the GnRH gene expression in other examined tissues 
(including dorsal prostate, lateral prostate, coagulating gIand, seminal vesicles, pituitary 
gland and hypothalamus of the normal Noble rat) by Southern blotting. 
The PCR products (263 bp) amplified with the SF2 and SR{ primers for the 
GnRH gene were used for Southern blotting and hybridized with the GnRH probe 
generated from the ventral prostate. All samples showed a hybridization band with the 
GnRH probe (Fig. 17b). The results of Southern blotting confirmed with the PCR that 
GnRH mRNA was expressed in dorsal prostate, lateral prostate, ventral prostate, 
coagulating gland, seminal vesicles, hypothalamus and pituitary gland. 
In addition to hypothalamus, expression of GnRH has been reported in extra-
hypothalamic tissues. For example, GnRH mRNA was detected in the rat anterior 
pituitary gland, human non-tumorous and neoplastic pituitaries by RT-PCR, Southern 
blotting and in situ hybridization (Pagesy et al., 1992; Sanno et al.’ 1997). On the other 
hand, Limonta and his co-workers have reported that GnRH mRNA is not expressed in 
the rat pituitary gland by using RT-PCR (Limonta et al.，1996). Our present results have 
re-confirmed with the report by Pagesy and colleagues (1992) that GnRH gene was 
expressed in the pituitary gland of normal Noble rat. 
The expression of GnRH has also been demonstrated in some reproductive 
organs, including rat ovary (Oikawa et al., 1990)，human placenta (Radovick et al., 
1990)，mouse mammary gland (Ikeda et al., 1995), mature rat and adult human testis 
(Bank et al., 1995). In our present study, we have demonstrated clearly at a molecular 
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level that GnRH mRNA was expressed in the adult rat male accessory sex glands 
including the ventral prostate, dorsal prostate, lateral prostate, coagulating gland and 
seminal vesicles. However, its endocrine functions in these organs still remain unclear. 
The detection of GnRH mRNA has been described in the human prostatic cancer and 
prostate cancer cell lines (Limonta et al., 1996). However, so far there has been no 
definite report on the identification of the gene expression of GnRH in normal prostate 
gland. Our current findings provide the first evidence that GnRH is probably produced 
locally in the normal Noble rat prostate gland. This new evidence leads us to speculate 
that GnRH may have some local biological significance in the regulation of prostatic 
functions such as secretory activity. 
4丄2 Expression of GnRH mRNA in dysplastic Noble rat prostate 
In the present study, Noble rat was used as the animal model for the study of 
carcinogenesis ofprostate gland. After a prolonged (4 or 9 months) treatment with both 
androgen (T) and estrogen (E2 or DES), a premalignant proliferative lesion ofprostate 
termed ‘dysplasia，，could be induced in different lobes of prostate (Leav et al., 1988). 
� This premalignant lesion, dysplasia, is believed to be identical to the prostatic 
intraepithelial neoplasm (PIN) in human prostate, and will further progress into 
carcinoma (McNeal and Bostwick, 1986). 
The results of both PCR and Southem blot hybridization confirmed that GnRH 
gene was expressed in different lobes of the Noble rat prostate after hormonal treatment 
for different periods (4 or 9 month) (Figs 4-7; 17b). 
This confirmed that GnRH gene was expressed in the dysplastic or androgen-
estrogen treated prostates. However, no significant difference in the GnRH 
� 
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hybridization signals was observed between the hormone-treated and the control 
untreated prostates. 
Expression of GnRH has been reported in some abnormal reproductive tissues, 
including human breast tissues with fibrocystic disease and invasive ductal cancer. 
However, quantitative comparison of the mRNA level by dot blot analysis does not 
reveal any significant difference between the non-malignant and malignant breast 
samples for the GnRH gene expression (KottIer at al” 1997). Moreover, GnRH is also 
expressed in some human breast carcinoma cell lines including ZR-75-1, MCF-7 and 
MDA-MB-231 (Harris et aL, 1991). On the other hand, GnRH gene expression is also 
described in a human androgen-dependent prostatic tumor cell line, LNCaP and in an 
androgen-independent prostatic tumor cell line, DU145 (Limonta et al., 1996). In 
summary, the GnRH gene was expressed in the dysplastic prostates of Noble rat 
induced by long term treatment with T+E2 or T+DES. The results provide an indication 
that GnRH may have some biological significance in the early premalignant stage of 
prostate carcinogenesis. 
4丄3 Expression GnRH mRNA in androgen-dependent rat Dunning 
prostatic tumor 
Dunning rat prostatic adenocarcinoma has been used as an animal model for the 
study ofprostatic cancer for over 30 years (Dunning, 1963). R-3327-H was the subline 
tumor used in the present study. This subline is characterized to be androgen dependent 
and described as well-differentiated prostatic adenocarcinoma (Isaac et al., 1981; 
Smolev et al., 1977a and 1977b). 
The results ofRT-PCR and DNA sequence analysis have confirmed that GnRH 
gene was expressed in the androgen-dependent rat Dunning R-3327-H tumor. 
Expression of both GnRH and its receptor has been reported in a human androgen-
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dependent prostate cancer cell line, LNCaP (Limonta et aL, 1992 and 1996). The 
authors also described an experiment using GnRH agonist to treat the LNCaP cells and 
found that the agonist can inhibit the growth ofprostate cancer cells. The inhibition by 
the GnRH agonist is believed to be mediated by the GnRH receptor expressed by the 
LNCaP cells. However, the authors did not show any evidence for the expression ofthe 
GnRH receptor in the LnCaP cells. However, these studies have provided an insight 
into the clinical application of GnRH analogs for prostate cancer. The analogs might 
have a local inhibitory effect on the prostate gland, in addition to their effect on the 
pituitary. The authors also propose a mechanism of GnRH or its analog on the prostate 
cancer cells, possibly acting as a growth inhibitory factor through reducing the 
epidermal growth factor (EGF) binding sites in the autocrine-paracrine control of the 
androgen-dependent proliferation of prostatic tumor cells (Limonta et aL’ 1996). 
Moreover, functional GnRH receptor is also reported to be expressed in an androgen-
dependent rat Dunning tumor R-3327-H subline and demonstrated indirectly by using 
labelled GnRH analogs (Fekete et al” 1989; Jungwirth et al” 1997). In addition, 
experiments using GnRH analogs have shown that GnRH analogs can inhibit the 
growth as well as down-regulate the expression ofthe GnRH receptor in the Dunning 
prostatic tumor (Jungwirth et al., 1997). The exact mechanism ofaction ofthis GnRH 
analog on the hormone-dependent Dunning prostate cancer model remains unclear but 
it is suggested to be mediated via the GnRH receptor expressed in the tumor cells. In 
the present study, it is shown that GnRH mRNA is expressed and this peptide hormone 
is probably synthesized endogenously in this androgen-dependent rat prostate tumor. 
However, the physiological role of the local GnRH system is presently unknown, and it 
is postulated that GnRH may function in an autocrine-paracrine mode on the growth of 
the androgen-dependent rat prostatic tumor. 
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4.L4 Expression ofGnRHmRNA in AITtumor 
Similarly, the expression of GnRH mRNA was examined in another rat prostate 
carcinoma line: the androgen-independent prostatic tumor (AIT) of Noble rat. The 
tumor used in the present study was maintained in the castrated Noble rat (Ho et al., 
1988). 
The results on the PCR amplification and sequence analysis of the amplified 
cDNA fragment confirmed that GnRH mRNA was also expressed in the androgen-
independent prostatic carcinoma line of Noble rat. In the Southern blot analysis, the 
result showed that GnRH mRNA expression is significantly down-regulated as 
compared to its expression in the normal rat prostate and the Dunning rat tumor. 
Expression of GnRH has been reported in a human androgen-independent 
prostate cancer cell line，DU145 (Limonta et aL, 1996). In mammals, the biosynthesis 
and secretion of GnRH by the hypothalamus are regulated by a complex feedback 
mechanism by the steroid hormones such as estrogen and testosterone. Physiological 
studies in mammals and human have demonstrated changes in the hypothalamic GnRH 
secretion and its content under various steroid hormone conditions. For examples, 
Rudensten and co-workers (Rudensten et al., 1979) showed that castration can lower 
the release of GnRH from the hypothalamus and testosterone replacement in the 
castrated rats can restore the release of the hormone from the hypothalamus. A similar 
decrease in GnRH release from the hypothalamus is observed in the 
hypophysectomized rats and this decrease can be prevented by treating the 
hypophysectomized rats with testosterone. This suggests that the positive feedback 
control on the release of hypothalamic GnRH by testosterone is not mediated via the 
luteinizing hormone and/or follicle-stimulating hormone. However, the estrogen control 
on the hypothalamic release and content of GnRH still remains controversial. For 
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example, Dong and co-workers have shown that estrogen could down-regulate the 
promoter activity of GnRH in the transfected placental tumor cells JEG (Dong et al., 
1996). Estradiol can increase the GnRH release from the hypothalamus and thus induce 
LH surges in the rat (Park et al., 1989). However, estradiol has been shown to increase 
the GnRH secretion in the cultured ovine pituitary (Laws et aL，1990). 
The down-regulation of the GnRH expression observed in the AIT may 
probably be related to androgen and estrogen regulation. AIT was originally developed 
from an estrone-treated Noble rat O^oble and Hoover, 1975; Noble, 1977b and 1980a) 
and the original Nb-2Pr-E tumor line is an estrogen-dependent transplantable 
adenocarcinoma. Moreover, this tumor is maintained in the castrated rats. Dong and co-
workers have shown that estrogen could down-regulate the promoter activity of the 
GnRH gene in the transfected placental tumor cells, JEG, which is positive for the 
GnRH expression (Dong et aL, 1996). However, the molecular mechanisms underlying 
the regulation of GnRH gene expression by estrogen and androgen in AIT is largely 
unclear. It is speculated that the down-regulation of the GnRH expression in the AIT 
may be due to the effect of estrogen and androgen ablation. 
4.2 Detection of GnRH receptor expression in normal and 
neoplastic rat prostates 
4.2.1 Negative expression of GnRH receptor in normal and dysplastic 
Noble rat prostates 
Two approaches, including PCR and Southern blotting using a specific probe 
generated from the rat pituitary gland, were used to detect the mRNA expression of 
GnRH receptor in the normal and steroid-treated Noble rat prostates. The results ofboth 
Southern blotting (Figs. 28b-30b) and PCR (Figs. 31 and 32) confirmed that GnRH 
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receptor mRNA is only expressed in the pituitary gland but not expressed in the normal 
and dysplastic rat prostate. 
The expression ofboth GnRH and GnRH receptor mRNAs has been reported in 
the pituitary tissues and pituitary cells. Using RT-PCR and in-situ RT-PCR analyses, 
both GnRH and GnRH receptor mRNAs are detected in the human non-tumorous 
pituitaries and also in a mouse gonadotroph cell line, aT3-l (Sanno et al., 1997). In our 
present study, we confirmed that both GnRH and its receptor mRNAs were expressed in 
normal and hormone-treated pituitary glands. This observation suggests that GnRH 
gene is expressed and the peptide hormone may probably be synthesized in the pituitary 
gland, in addition to its well-known expression in the hypothalamus. The expression of 
both hormone and its receptor also suggests that there could be some paracrine or 
autocrine regulatory mechanisms operating in these normal and hormone-treated 
pituitary tissues. 
Extra-pituitary expression of GnRH receptor has been mentioned in some 
reproductive tissues and their derived tumor cell lines. Using RT-PCR and Southern 
blotting analysis, Kakar and co-workers (Kakar et al” 1994) have detected the gene 
expression of GnRH receptor in human breast, ovary, prostate as well as their derived 
tumors and tumor cell lines (including two breast tumor cell lines, MCF-7 and MDA_ 
MB 468; and two prostatic tumor cell lines, PC-3 and LNCaP). On the other hand, 
Ikeda and co-workers (Ikeda et al” 1995) have reported that GnRH mRNA is expressed 
in the mouse mammary glands at mid-pregnant, lactating and post-Iactational stages, 
whereas GnRH receptor mRNA transcripts are not detected in the mammary glands of 
any functional stage. It is suggested that GnRH may be involved in the local regulation 
of the involutionary processes of the mammary gland. Similar studies on human 
prostate samples are scarce and results are fragmentary. Feketa and co-workers (Feketa 
7 6 
et al.，1989) have shown that among 13 human benign prostatic hyperplastic samples 
examined, only one sample showed positive result for the GnRH receptor. In the same 
study by Feketa and co-workers, GnRH receptor expression was detected in the human 
prostate cancer but not in the normal prostate. 
Preliminary experiments have been performed to localized the cell types in the 
prostate gland expressing the hormone GnRH by in-situ hybridization and 
immunohistochemistry for the GAP protein. However, negative results were 
demonstrated and this was explained by their very low expression in these tissues. 
Therefore, it is unknown which cell types in the prostate gland are expressing the GnRH 
gene. In the present study, GnRH mRNA was detected in the individual lobes ofnormal 
and dysplastic prostatic glands, whereas the expression of its receptor was not detected 
in the same tissues. The expression of GnRH gene indicates that this peptide hormone 
may be synthesized and released locally in these male accessory sex glands. However, 
the biological significance of the local GnRH expression by normal and dysplastic 
prostates is still uncertain and requires further verification. At the present stage, we 
speculate that the functional significance of the local expression of GnRH in the rat 
prostate gland: (1) the expression of GnRH in normal and dysplastic Noble rat prostates 
may be regarded as non-functional since its functional receptor is not detected; (2) 
synthesis of GnRH by the normal and dysplastic prostates may be released to blood 
circulation and acts on other target organs. The second explanation is unlikely as the 
peptide hormone will be rapidly degraded by the serum proteinases and also a portal 
circulatory system is absent in the prostate gland. 
4.2.2 Positive expression of GnRH receptor mRNA in rat Dunning 
tumor 
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In the present study, the results of the combined RT-PCR and Southem blotting 
using a specific GnRH receptor probe generated from the pituitary gland, and the 
sequence analysis confirmed that GnRH receptor mRNA was expressed in the rat 
Dunning tumor (Figs. 33b and 34). 
Our results re-confirmed with the previous reports that GnRH receptor, but not 
the GnRH, is expressed in the Dunning rat prostate tumor (Fekete et al., 1989; Pinski et 
flf/.，1993; Jungwirth et al., 1997). Moreover, we have also demonstrated for the first 
time that GnRH gene is also expressed in this tumor. 
The inhibitory effects of the GnRH analogs demonstrated on the growth of the 
Dunning prostate cancer cells are attributed to the positive expression of GnRH receptor 
in the cancer cells (Jungwirth et al., 1997). The effects of the GnRH analogs also 
suggests that there is an inhibitory role ofthe locally synthesized GnRH on the growth 
ofthis tumor. In summary, the expression ofboth GnRH and its receptor in the Dunning 
prostatic tumor suggests that this locally synthesized hormone may serve an autocrine 
or paracrine regulatory control on the growth ofprostate cancer cells. 
4.2.3 Negative expression ofGnRH receptor mRNA in AIT tumor 
The mRNA expression of GnRH receptor in the AIT tumor was detected by two 
PCR amplifications. The results showed that the GnRH receptor was not expressed in 
the AIT (Figs. 36 and 37). Using receptor assays, GnRH binding sites are detected in a 
human androgen-independent tumor cell line, DU145 (Limonta et al., 1996)，and in an 
androgen-independent Dunning rat tumor R-3327-AT-l tumor (Pinski et al., 1994). 
Studies on the androgen-independent Dunning rat R-3327-AT-l show that the receptor 
for epidermal growth factor (EGF) is down-regulated by treatment with GnRH agonist 
and antagonist and this treatment can inhibit the growth ofthe tumor. 
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The present observation on the expression of GnRH receptor in two prostate 
tumor models: androgen-dependent Dunning tumor (with positive expression ofGnRH 
receptor) and androgen-independent prostate tumor of Noble rat (with negative 
expression of GnRH receptor), suggest that the mechanism of action of GnRH may be 
different in different prostate cancers depending on whether the prostate tumor cells are 
androgen-dependent or -independent and their endocrine control ofgrowth may be also 
different. In the case of the androgen-dependent Dunning tumor, testosterone is the 
major exogenous stimulus for the growth ofthe tumor and the androgen probably acts 
indirectly on the growth of tumor cells by increasing the activity of the locally 
expressed growth factor system particularly EGF (Berns et al., 1983; Horoszwicz et al” 
1983; Schuurmans et al., 1991; Henttu et al.’ 1992). The expression ofboth GnRH and 
its receptor in the Dunning tumor suggests that this peptide hormone probably 
participates in this local expressed growth factor system. Whereas in the androgen-
independent prostate tumor ofNoble rat, the growth ofthe tumor, as similar to human 
androgen-independent prostate cancer cells, is regulated by peptide growth stimulatory 
factors, such as the interaction of epidermal growth factor (EGF) with the locally 
expressed insulin-like growth factor and TGFa system (ConoIly and Rose, 1991 and 
1994). Since GnRH receptor is probably not expressed in the AIT, the locally 
expressed GnRH in this tumor, instead of interacting with its own receptor, may 
possibly influence the growth of tumor by counteracting the stimulatory action ofEGF. 
Studies in the androgen-independent tumor cells, DU145, GnRH analog is shown to 
decrease the concentration of EGF-binding sites (or receptors) and by antagonizing the 
EGF-activated tyrosine phosphorylation of the EGF receptor (Limonta et al., 1996). 
However, the exact mechanisms of action of GnRH in the normal and neoplastic 
prostates still remains to be verified. 
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Chapter 5. Summary and Conclusions 
In the present study, three animal models including the hormone-inducible 
Noble rat model, androgen-dependent Dunning R-3327-H rat prostatic tumor and 
androgen-independent prostatic tumor (AIT) derived from Noble rat which represent 
the different stages of prostate cancer were used to investigate the expression of 
gonadotropin-releasing hormone and its receptor in the prostate. The gene expression of 
this peptide hormone and its receptor was detected by molecular biological techniques 
including RT-PCR, DNA sequencing and Southern blot hybridization. 
In the normal Noble rat, our studies have demonstrated clearly at a molecular 
level，that GnRH mRNA was expressed in the major adult rat male accessory sex glands 
including the ventral prostate, dorsal prostate, lateral prostate, coagulating gland and 
seminal vesicles. In the hormone-inducible Noble rat model, Noble rats under 
prolonged (4 or 9 months) treatment with both androgen (T) and estrogen (E2 or DES), 
developed a premalignant lesion of prostate termed ‘dysplasia，，induced mainly in the 
ventral and lateral lobes of the prostate. In the present study, we have confirmed that the 
GnRH gene expression persisted in different lobes of the hormone-induced dysplastic 
Noble rat prostate (including the ventral prostate, dorsal prostate and lateral prostate). 
However, the expression of GnRH receptor mRNA in the normal and dysplastic Noble 
rat prostate was found to be negative. 
In the present study, GnRH mRNA was detected in the individual lobes of 
normal and dysplastic prostate gIand, whereas the expression of its receptor was not 
detected in the same tissues. The positive expression of GnRH gene indicates that this 
peptide hormone may be synthesized and released locally in these male accessory sex 
glands. However, the biological significance of the local GnRH expression by the 
normal and dysplastic prostates still remains unclear and requires further verification. 
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Dunning R-3327-H rat prostatic tumor is characterized to be androgen-
dependent and described as a well-differentiated adenocarcinoma. In the present study, 
it has been found that both GnRH as well as its receptor mRNAs were expressed in this 
androgen-dependent rat prostatic tumor. In previous studies, it has been shown that 
analogs of GnRH can inhibit the growth of a human androgen dependent prostate 
cancer cell line, LNCaP and rat Dunning tumor R-3327-H subline probably by reducing 
the binding sites for epidermal growth factor (EGF) and also down-regulating the 
expression of GnRH receptor. Our results have demonstrated that the inhibitory effect 
of GnRH analogs may be mediated by the GnRH receptor expressed in the prostate 
tumor cells. In summary, we suggest that the locally expressed GnRH and it receptor in 
R-3327-H rat prostate tumor may serve as an autocrine or paracrine inhibitory regulator 
on the growth of prostate cancer cells. 
Similarly, the expression of GnRH mRNA was also confirmed in the androgen-
independent prostatic tumor (AIT) ofNobIe rat. AIT was originally developed from an 
estrone-treated Noble rat, and maintained in the castrated Noble rats. In the Southem-
blot analysis, the results showed that GnRH mRNA expression was significantly down-
regulated as compared to its expression levels in the normal rat prostate and Dunning 
rat tumor. The down-regulation of the GnRH expression in the AIT is speculated to be 
related to the origin from which the prostate tumor was developed under long-term 
treatment with estrogen and maintained under androgen ablation condition. However, 
the molecular mechanism of GnRH gene expression regulated by estrogen and 
androgen in the AIT is unclear. 
Although GnRH gene was expressed in AIT tumor, GnRH receptor was not 
detected in the tumor. Since GnRH receptor is not expressed in the AIT, the locally 
synthesized GnRH in the AIT possibly interacts with other growth factor and receptor 
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systems such as EGF, but not with its own receptor in order to exert inhibitory effects 
on the growth of tumor. However, the exact mechanism of the action of locally 
synthesized GnRH in the normal and neoplastic prostates still remains to be verified. 
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